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ABBREVIATIONS 
 
ACA Anterior cerebral artery 
AIF Apoptosis-inducing factor 
Ampa D,L-α-amino-3-hydroxy-5-methyl-isoxazolpropionic acid 
ASICs Acid-sensing ion channels  
BA Basilary artery 
BBB Blood-brain barrier 
Bcan Brevican 
Bdnf Brain derived neurotrophic factor 
CAP23 Membrane attached signal protein 1 
Cat Catalase 
CBF Cerebral blood flow 
CI Confidence intervall  
C-jun Jun proto-oncogene 
CT  Computed tomography  
CTA Computed tomography angiography 
Cuzd1 CUB and zona pellucida-like domains 1 
Cxcl 12 Chemokine (C-X-C motif) ligand 12  
CXCL8 C-X-C motif ligand 8 
Cybb Cytochrom b-245, beta polypeptide 
Csnk2b Casein kinase 2 beta 
Cspg4 Chondroitin sulfate proteoglycan 4 
DAB 3,3-diaminobenzidine 
DAPT Dual anti-platelet therapy 
DCC Deleted in colorectal carcinoma 
DHC Decompressive hemicraniectomy 
DISC Death inducing signaling complex 
DQ gelatin Dye-quenched gelatin 
Egfr Epidermal growth factor receptor 
ELVO Emergent large vessel occlusion 
EphB1 Eph receptor B1 
EU European union 
FADD Fas associated death domain 
Flt1 FMS-related tyrosine kinase 
GAP 43 Growth associated protein 43 
GAPDH Glyceraldehid 3 phosphate dehydrogenase 
Gpx1 Glutathion peroxidase 1 
Hif1a Hypoxia inducible factor 1, alpha subunit 
IAT Intra-arterial therapy 
Iba1 Ionized calcium-binding adapter molecule 1  
ICA Internal carotid artery 
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Icam1 Intercellular adhesion molecule 1 
ICH Intra-cerebral hemorrhage 
Igf1 Insulin-like growth factor 1 
Igfbp6 Insulin-like growth factor binding protein 6 
IL1ᵦ Interleukin 1 beta 
Infg Interferon gamma 
IS Ischemic stroke 
Jag1 Jagged 1 
Kdr Kinase insert domain receptor 
L1 cam L1 cell adhesion molecule 
LDF Laser doppler flowmetry 
Lingo 1 Leucine rich repeat and Ig domain containing 1  
LOC  Level of consciousness 
Lrp1  LDL receptor related protein 1 
LVO Large vessel occlusion 
Mag Myelin associated glycoprotein 
MAO B  Monoamine oxidase B 
Marcks Myristoylated alanine rich protein kinase 
MCA-M1 Middle Cerebral Artery proximal segment 
MCA-M2 Middle Cerebral Artery first division side branch 
Mmp12 Matrix metalloproteinase 12 
Mmp2 Matrix metalloproteinase 2 
Mmp9 Matrix metalloproteinase 9 
Mog Oligodendrocyte glycoprotein 
MRI Magnetic resonance imaging 
mRNA Messenger ribonucleic acid 
mRS Modified rankin scale 
MTP Mitochondrial transition pores 
MWW Mann-whitney-wilcoxon 
Ncan Neurocan 
NCBI National Center fo Biotechnology Information 
nDNA Nuclear deoxiribonucleic acid 
NFM Neurofilament N 
Ngf Nerve growth factor (beta polypeptide)  
Ngfr (P75NTR) Nerve growth factor receptor 
NICD Intracellular domain of Notch1 
NIHSS National Institute of Health Stroke Scale 
NMDA N-methyl-D-aspartate 
Notch 1 Notch 1 
Nogo receptor Alternative name of the Reticulon 4 receptor 
Nrp1 Neuropilin  
NSA Number of signal averages 
Ntn 1 Netrin1 
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NVU Neurovascular unit 
P21 Cyclin dependent kinase inhibitor1a 
PARP Poly (ADP-ribose) polymerase 
PCA Posterior cerebral artery 
PCR Polimerase chain reaction 
PirB  Paired Ig-like-receptor B 
Plat Plasminogen activator, tissue type 
Ptprz1 Protein tyrosine phosphatase receptor Z1 
Rac1 Ras-related botulinum toxin substrate 1 
RCT Randomized controlled trial 
RECA Rat endothelial cell antigen 
ROS Reactive oxigen species 
Rtn4 Reticulon 4 (nogo a) 
Rtn4r Reticulon 4 receptor (Nogo receptor) 
SAH Subarachnoid hemorrhage 
Sele Selecin E 
Sema3a Semaphorin 3A 
Sod1 Superoxide dismutase 1 
Sod2 Superoxide dismutase 2 
SPRR1 Small proline-rich protein 1 
Stat3 Signal transducer and activator of transcription 
TBST Tris-buffer saline tween 
TE  Echo time 
TGFᵦ 1 Transforming growth factor, beta 1 
TIA Transient ischemic attack 
TICI Thrombolysis in Cerebral Infarction 
TIMP1 Tissue inhibitor of metalloproteinase 1 
TIMP2 Tissue inhibitor of metalloproteinase 2 
TIMP3 Tissue inhibitor of metalloproteinase 3 
TIMP4 Tissue inhibitor of metalloproteinase 4 
tMCAO Transient Middle Cerebral Artery Occlusion 
Tnf Tumor necrosis factor 
TR  Repetition time 
TTC  Tetraphyenil tetrazolium chloride 
UV Ultra violet 
VA Vertebral artery 
Vcam1 Vascular cell adhesion molecule 
Vcan Versican 
Vegfa Vascular endothelial growth factor a 
VISTA Volume isotropic Turbo spin echo Acquisition 
vWF Von Willebrand factor 
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EXPERIMENTAL INVESTIGATION OF POTENTIAL NEW THERAPEUTIC 
TARGETS IN CEREBRAL LARGE VESSEL OCCLUSION 
INTRODUCTION 
Definitions 
 
A stroke is the acute neurologic injury occurring as a result of brain ischemia or brain 
hemorrhage.  
Brain ischemia is either due to thrombosis, embolism, or systemic hypoperfusion, while brain 
hemorrhages can be classified into intra-cerebral hemorrhage (ICH) and subarachnoid 
hemorrhage (SAH) (Caplan (2009). 
Our current work focuses on the cerebral infarcts caused by emergent large vessel occlusions 
(ELVO). These ischemic strokes (IS) develop as a consequence of a proximal thrombotic 
blockage of the intra-cranial arteries, and their natural history is most often characterized by 
poor functional outcomes and high mortality rates (Lima et al., 2014).  
While the findings of our preclinical investigations may have implications for other stroke 
subtypes, the transient middle cerebral artery occlusion (tMCAO) model used in our 
experiments most accurately simulates the pathophysiology of the ELVO, therefore we will 
limit our conclusions to this well-defined clinical entity. Chronic causes of intra-cranial large 
vessel occlusion, including Moya-Moya disease are beyond the scope of our dissertation due 
to their fundamentally different pathobiology.  
Epidemiology of stroke and ELVO 
 
Stroke is the second most common cause of mortality and the third most common cause of 
disability worldwide. The incidence rate of stroke is changing inversely in the high- and low-
income countries, with an increasing incidence in the low-income group (Krishnamurthi et 
al., 2013) (Fig. 1.). While the overall rate of stroke-related mortality is decreasing worldwide, 
the absolute number of people with stroke, stroke survivors, stroke-related deaths, and the 
global burden of stroke-related disability is high and increasing (Feigin et al., 2014). 
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Figure 1. Age-standardized incidence of ischemic stroke per 100 000 person-years for 1990 
(A) and 2010 (B). During the last 20 years incidence rates were changing in the opposite 
directions in the high- and low- income countries (Krishnamurthi et al., 2013). 
Globally, the incidence of stroke due to ischemia is 68 percent, while the incidence of 
hemorrhagic stroke (ICH and SAH combined) is 32 percent, reflecting a higher incidence of 
hemorrhagic stroke in low- and middle-income countries (Krishnamurthi et al., 2013).  
Following multiple imaging studies reporting a broad range of incidence rates, the first 
prospective registry evaluating the frequency of ELVO among all-comer patients admitted 
for thrombolysis work up was conducted in the Capital Region of Denmark between July 
2009 and December 2011 (Hansen et al., 2015). Among the 885 patients evaluated for the 
suspicion of hyper-acute stroke within 4.5 h after symptom onset, computed tomography 
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angiogram (CTA) was performed in 637 subjects, including 475 patients with a final 
diagnosis of IS (74.6%) and 162 (25.4%) diagnosed with transient ischemic attack (TIA). 
The rest of the patients were excluded from analysis due to ICH (n=99), stroke mimics 
(n=147) or technical reasons (n=2). Altogether 28.7% (n=183) of the patient undergoing CTA 
had large vessel occlusion with 15 different anatomical distributions (Fig. 2). Based on these 
results more than one out of five patients evaluated for thrombolysis harbored ELVO.  
Important to note, that the majority of the large vessel occlusions involve the middle cerebral 
artery territory, confirming the adequacy of the tMCAO experiments for modelling this 
pathology.  
 
Figure 2. Anatomical distribution of large vessel occlusions. Number and % of patients with 
intra-cranial occlusions and their median National Institute of Health Stroke Scale (NIHSS) 
score in single vessel (A) and multiple vessel (B) disease. (Hansen et al., 2015) 
Currently no epidemiologic data is available on the frequency of ELVO in Hungary. The 
country-specific figures published recently in the framework of the EuroHope Register 
however suggest a particularly high incidence of hospitalization (407/100000) and a high 
case fatality rate (31% at 1 year) of stroke among the Hungarian population compared to 
other studied European Union countries (Malmivaara et al., 2015). While the authors have 
raised some queries about the reliability of the administrative data derived from hospital 
discharges, a more severe initial presentation of the stroke cases together with a potentially 
higher frequency of ELVOs due to the lack of effective cardiovascular prevention may also 
be responsible for the documented excess mortality.   
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The natural history of ELVO 
A proximal occlusions in the main intra-cranial arteries affect large brain territories by 
severely decreasing their perfusion. In a prospective registry of patients with untreated, 
unilateral ELVO of the anterior circulation, less than half of the observed subjects (44%) 
could achieve functional independence, and almost one-fourth (22%) of them were dead at 6 
months.  The only predictors for good functional outcome at 6 months were less severe 
neurological status (NIHSS<11) at presentation (see Appendix), younger age, and better 
collateral circulation (Lima et al., 2014).  
The adverse outcomes associated with the ELVOs are not only the consequence of the 
extensive loss of functional neuronal circuits, but the larger infarct size itself is also an 
independent predictor of symptomatic hemorrhagic transformation, which leads to further 
neurological worsening and potentially excess mortality (Tan et al., 2014).  
Another dreadful complication of the ELVOs is the malignant middle cerebral artery 
syndrome, which is characterized by a complete infarction of the MCA territory accompanied 
by the mass effect of a space occupying edema. The malignant evolution of the infarction 
develops within 5 days of symptoms onset, and it is associated with about 80% mortality if 
left untreated (Hacke et al., 1996). The early identification of patients who are most likely to 
develop malignant edema after MCA infarction is of paramount importance to plan the 
necessary interventions, including a timely performed decompressive hemi-craniectomy 
(DHC) if necessary.  
Many clinical variables were proposed as surrogate markers for adverse evolution. A fairly 
low positive predictive value can be attributed to NIHSS >20, thrombus at the carotid 
terminus location, and early involvement of >50% of the MCA territory on native CT. 
Specificity is raised by the more precise volumetric analysis of the infarct size using MRI 
diffusion-weighted imaging: an infarct volume of >145cm3 measured within 14 hours of 
symptom onset detected patients at high risk with 100% sensitivity and 94% specificity.  
Based on the results of randomized trials, early DHC significantly reduces mortality after 
malignant MCA infarction; however, it also increases the probability of survival with 
moderately severe disability. The early timing of the surgery is crucial in achieving favorable 
outcomes, and it appears to benefit younger patients the most (Staykov and Gupta, 2011).  
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Reperfusion therapy in ELVO 
Until very recently, intravenous alteplase administered within 4.5 hours after symptom onset 
was the only reperfusion therapy with proven efficacy in patients with acute IS (Emberson et 
al., 2014). Besides the broad range of contra-indications of this therapeutic modality, 
including coagulopathy, recent surgery and previous intra-cranial bleeding, systemic 
thrombolysis was proven to be much less effective in opening proximal occlusions. In the 
ELVO cases involving the ICA terminus the early recanalization rate was only about 30% 
using thrombolysis (Christou et al., 2001).  
In 2015, five randomized clinical trials (Table 1) proved the higher efficacy of mechanical 
thrombectomy in the treatment of emergent LVOs compared to systemic thrombolysis, 
significantly changing the therapeutic recommendations for IS (Wahlgren et al., 2016). While 
the thorough presentation of these fundamental trials is beyond the scope of the thesis, some 
details are important to support the foundations of our experimental work. 
Table 1. Recent randomized controlled trials of mechanical thrombectomy in LVO  
Study name and 
reference 
# of 
patients 
TICI 
2b/3 
flow 
Median 
NIHSS 
T/C 
sICH 
% 
T/C  
Difference 
in good 
outcome* 
Time 
from 
onset 
Onset to 
groin 
time 
Mortality 
%  
T/C 
MR CLEAN 
(Berkhemer et al., 
2015) 
500 59% 17/18 7.7/6.4 +14% <6h 4h20m 21/22 
ESCAPE 
(Goyal et al., 
2015) 
316 72% 17/16 3.6/2.7 +24% <12h 4h01ma 10/19 
EXTEND-IA 
(Campbell et al., 
2015) 
70 89% 17/13 0/2.9 +31% <6h 3h30m 9/20 
SWIFT PRIME 
(Saver et al., 
2015) 
196 83% 17/17 0/3 +25% <6h 4h12m 9/12 
REVASCAT 
(Jovin et al., 
2015) 
206 66% 17/17 1.9/1.9 +16% <8h 4h29m 18/16 
         
Table 1. Selected date from the five recent RCTs on mechanical thrombectomy show that 
faster and more effective recanalization leads to better outcome. *Functionally independent 
patients (mRS 0-2 at three months) a Time to reperfusion.  
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In contrast with the previous unsuccessful studies (Broderick et al., 2013; Kidwell et al., 
2013), the new trials showing the improved functional outcomes associated with mechanical 
thrombectomy had some important common features. Only patients with confirmed large 
vessel occlusions were included, and the operators were able to rapidly achieve complete 
recanalization (TICI2b/3 flow) rate in a high proportion of the enrolled patients using the 
new generation stent retriever devices (Table 1). A recently published meta-analysis of the 
five trials showed similar positive results as the individual reports, and it also confirmed the 
efficacy of thrombectomy in patients who were not eligible for thrombolysis (Goyal et al., 
2016) (Fig. 3, Table 2). 
 
Figure 3. Functional outcomes of mechanical thrombectomy. Distribution of modified 
Rankin Scale scores at 90 days in the intervention and control groups in the overall trial 
population (A) and for patients treated with, or ineligible for intravenous alteplase (B). Data 
from the metaanalysis of the five RCTs (Goyal et al., 2016). 
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Table 2. Modified Rankin Scale (van Swieten et al., 1988)  
0 No symptoms. 
1 No significant disability. Able to carry out all usual activities, despite some symptoms. 
2 Slight disability. Able to look after own affairs without assistance, but unable to carry 
out all previous activities. 
3 Moderate disability. Requires some help, but able to walk unassisted. 
4 Moderately severe disability. Unable to attend to own bodily needs without assistance, 
and unable to walk unassisted. 
5 Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 
6 Dead 
  
Table 2. Standardized classification of functional outcomes following neurological injury 
according to Modified Rankin Scale (van Swieten et al., 1988). 
The speed of recanalization is probably the most important factor determining the efficacy 
of thrombectomy (Fig. 3), as the amount of salvageable brain tissue and the chances of 
achieving good perfusion both steadily decrease with time. For every hour of reperfusion-
delay, the initially large benefit of IAT decreases; the absolute risk difference for a good 
outcome is reduced by 6% per hour of delay (Fransen et al., 2016). 
While the importance of optimizing the time window cannot be overemphasized, we have to 
keep in mind that some optimally chosen patients with good collaterals may also benefit from 
thrombectomy beyond 6 hours from the onset of symptoms (Goyal et al., 2015).   
There is an ongoing debate over the optimal use of imaging modalities to select patients for 
mechanical reperfusion therapy, especially to identify potential candidates among the late 
presenters. CT based perfusion imaging (Campbell et al., 2015) and the imaging of collaterals 
(Goyal et al., 2015)  were both used in the recent clinical trials, and with certain limitations, 
they both proved to be fairly accurate in guiding patient selection. Yet other authors claim 
that MRI may be the ideal modality (Wouters et al., 2016), as the DWI/perfusion mismatch 
clearly defines the unviable territory as well as the salvageable brain tissue. The optimal 
selections criteria for such patients is yet to be determined by further clinical research. 
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Safety issues of thrombectomy: prevention of bleeding complications and re-infarction 
A very important aspect of the interventional treatment of ELVOs is the safety of the 
procedures. The analysis of the procedural complications did not show any excess bleeding 
or mortality associated with the more invasive interventional treatment (Table 3). We have 
to remember however, that the systemic thrombolysis alone already increases bleeding risk 
compared to the conservative management without reperfusion therapy, causing an average 
absolute increased risk of early death from ICH of about 2% (Emberson et al., 2014).  
Therefore further development is needed to prevent the reperfusion associated ICH, and the 
efficacy of thrombectomy alone in thrombolysis eligible patient should be also tested in new 
randomized controlled trails.   
Table 3. Safety outcomes of the recent RCTs of mechanical thrombectomy at 90 days 
 
Interventional 
population 
Control 
population 
Risk 
difference 
Odds ratio 
(95% CI) 
Symptomatic ICH 4.4% (28/634) 4.3%(28/653) 0.1 % 
1.07 (0.62-1.83) 
p = 0.81 
Parenchymal 
hematoma type 2* 
5.1% (32/629) 5.3%(34/641) -0.2% 
0.99 (0.6-1.63) 
p = 0.97 
Mortality 
15.3% 
(97/633) 
18.9%(122/646) -3.6% 
0.73 (0.47-1.13) 
p = 0.16 
     
Table 3.  Meta-analysis of the safety outcomes of the five recent thrombectomy trials showed 
no risk difference between the treatment groups (Goyal et al., 2016)  *Blood clot occupying 
>30% of the infarcted territory with substantial mass effect. 
The optimal estimation of the hemorrhagic and thrombotic risk of each individual patient is 
crucial for optimizing treatment outcomes. The actual stroke etiology as well as the extent of 
the brain damage has to be taken into account while determining the timing and composition 
of the antithrombotic regimen following cerebral large vessel recanalization. Evidence from 
a randomized trial confirms, that in the first 24 hours following treatment with 
intravenous alteplase, aspirin or other antithrombotic agent should not be given (Zinkstok 
and Roos, 2012).  Afterwards the use of early aspirin (160 to 325 mg/day) rather than no 
aspirin therapy or early anticoagulation is recommended for most patients with acute 
ischemic stroke or TIA (Jauch et al., 2013; Lansberg et al., 2012). Early parenteral 
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anticoagulation rather than aspirin is only suggested for select patients with acute cardio-
embolic ischemic stroke, who have a high suspicion for intracardiac thrombus, as these 
patients are at high risk for recurrent ischemic stroke. In atrial fibrillation, early therapeutic 
anticoagulation following acute stroke should be reserved to those harboring only minor 
intracerebral lesions based on control imaging, since in unselected patients the clinical benefit 
from the prevention of recurrent strokes was offset by the excess occurrence of intra-cranial 
bleeds (Sandercock et al., 2015). 
Stroke patients presenting with significant intracranial large vessel stenosis represent a 
special subgroup, and according to recent evidence, they require early double anti-platelet 
therapy (DAPT) with the combination of aspirin and clopidogrel (Derdeyn et al., 2014). 
Patients receiving carotid stents as part of their acute stroke treatment also require DAPT 
after the exclusion of hemorrhagic transformation.  
Important to note, that current antithrombotic strategies are mainly based on data from the 
old randomized trials of thrombolysis, therefore their validity following thrombectomy is not 
proven. Due to the fundamentally different recanalization efficacy and hemodynamic effect 
of the two reperfusion modalities, there is an urgent need for new RCTs in order to gather 
further evidence guiding the antithrombotic therapy following thrombectomy.  
Another important, but currently less emphasized source of major complications in 
interventional stroke treatment is the access site bleeding. Due to the common co-occurrence 
of peripheral arterial disease and stroke, and the current therapeutic guidelines supporting the 
combined use of thrombolysis and thrombectomy, femoral artery punctures carry a non-
negligible risk. Data from a recent metaanalysis comparing the safety of access sites in acute 
percutaneous coronary intervention show, that the use of radial artery can reduce vascular 
complication’s rate and even mortality compared to femoral access (Ando and Capodanno, 
2015). Our group has published a randomized trial comparing radial and femoral puncture 
during carotid artery stenting, and our results confirmed, that radial puncture allows efficient 
access for the treatment of vascular lesions of the neck in most cases (Ruzsa et al., 2014). 
Our findings also implicate, that radial approach may be used for thrombectomy in the future 
to avoid the complications associated with femoral puncture.   
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Potential adjunctive strategies to improve the functional outcomes of ELVO  
The percutaneous revascularization of cerebral large vessel occlusions by mechanical 
thrombectomy is obviously a huge step forward in the optimal treatment of IS, and based on 
the above cited evidences the new therapeutic guidelines have given the highest level of 
recommendation for this treatment modality in eligible patients (Powers et al., 2015; 
Wahlgren et al., 2016). Ongoing clinical trials will help to further improve the patient 
selection in order to avoid the futile, and in some cases even harmful revascularizations. 
However there remains a large demand for the development of adjunctive therapies to offer 
alternative solutions to help the patients, who are non-eligible for reperfusion.  
The infarcted brain tissue represents the common final stage of various different cascade 
mechanisms of cellular apoptosis and necrosis.  The closely interrelated events occurring in 
the affected brain show a wide regional variety and diverse temporal pattern, making their 
investigation very challenging by conventional research methods. The system biology 
approach may provide a new insight into the pathophysiology of the brain vasculature (Clegg 
and Mac Gabhann, 2015), however the great amount of new information available at present 
time is not yet ready to formulate a new unifying concept for paving the foundations for new 
strategies of future stroke therapy.  
Besides improving the outcomes with early reperfusion therapy, neuroprotective strategies 
or the effective augmentation of post-ischemic neuro-restorative mechanisms could be an 
alternative method to improve the prognosis of patients suffering from ELVO, however these 
approaches are still very far from being established treatment modalities. In order to find new 
therapeutic targets in stroke therapy, a fundamental understanding of the pathophysiology of 
ischemic brain lesions is crucial. 
 In the subsequent sections we will present the results of our recent investigations of two 
different pharmacological interventions, subacute gelatinase inhibition and selegiline 
treatment on a standard experimental model of ELVO in rodents. While the two treatments 
have been shown to inversely influence the functional outcomes after focal ischemia, their 
mechanism of action has not been fully explored before. We used an mRNA expression array 
analysis to study the effect of the interventions on the genes influencing post-stroke recovery. 
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Overview of the key regulatory genes influencing post-stroke recovery 
The concept of the neurovascular unit (NVU) emphasizes the fact that neurons, astrocytes, 
smooth muscle cells, endothelial cells, pericytes, basement membranes, and the extracellular 
matrix all dynamically interact in the pathobiology of stroke (del Zoppo, 2009). The extent 
of recovery following brain injury is determined by the complex interplay of parallel 
processes involving the NVU, including synaptic and microvascular remodeling, 
inflammation, apoptosis, oxidative stress and structural alterations of the extracellular matrix. 
We sought to investigate the simultaneous changes induced by the two tested 
pharmacological interventions on the mRNA expression profile of the most important 
regulatory genes driving the remodeling processes of the penumbra. Despite the presentation 
of the key genes under distinct categories, it is important to keep in mind their redundancy, 
and their potential parallel regulatory roles.  
Stroke induces a process of axonal sprouting in the peri-infarct tissue that results in a 
substantial re-mapping of the connections of the cortical areas adjacent to the infarct. This 
post-stroke axonal sprouting response is correlated in location and magnitude with functional 
recovery (Calautti and Baron, 2003). Nervous system injury induces expression of both 
growth-promoting and growth-inhibitory genes that together determine the location and 
degree of axonal sprouting.  
The growth-promoting gene products (Table 4A) mediate growth cone membrane signaling 
events, transcriptional control in the regenerating neuron, cytoskeletal reorganization and 
axonal extension, and include GAP43, CAP23, MARCKS, c-jun, members of the stathmin 
family, Tα1 tubulin, L1, p21/waf1, and SPRR1. These proteins are specifically upregulated 
during sprouting, reduce axonal sprouting when knocked down or out, and mediate enhanced 
axonal sprouting when overexpressed (Benowitz et al., 2002; Bomze et al., 2001; 
Carmichael, 2003; Laux et al., 2000). 
Stroke induces sequential waves of neuronal growth-promoting genes during the sprouting 
response: an early expression peak (SPRR1), a mid expression peak (p21, Ta1 tubulin, L1, 
MARCKS), a late peak (SCG10, SCLIP), and an early/sustained pattern (GAP43, c-jun). The 
expression of the growth inhibiting genes (Table 4B) show biphasic pattern. The growth-
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inhibiting chondroitin sulfate proteoglycans aggrecan, brevican, versican, and phosphacan 
are induced late in the sprouting process; while  the developmentally associated growth 
inhibitors ephrin-A5, ephB1, semaphorin IIIa, and neuropilin 1 are induced in the early 
phases of the sprouting response. At the cellular level, chondroitin sulfate proteoglycans are 
reduced in the region of axonal sprouting, during the peak of growth-promoting gene 
expression (Carmichael et al., 2005). 
Table 4A Genes promoting axonal sprouting  
Abbreviation Name 
NCBI Reference 
Sequence 
GAP 43 Growth associated protein 43 NM_017195.3 
C-jun Jun proto-oncogene NM_021835.3 
CAP23 Membrane attached signal protein 1 NM_022300.1 
SPRR1 Small proline-rich protein 1 XM_574984.2 
P21 Cyclin dependent kinase inhibitor1A NM_080782.3 
L1 cam L1 cell adhesion molecule NM_017345.1 
Marcks Myristoylated alanine rich protein kinase XM_002728965.1 
DCC Deleted in colorectal carcinoma NM_012841.1 
Cuzd1 CUB and zona pellucida-like domains 1 NM_054005.1 
NFM Neurofilament N NM_017029.1 
Ntn 1 Netrin1 NM_053731.1 
Table 4B Sprouting inhibitor genes    
Ncan Neurocan NM_031653.1 
Vcan Versican NM_001170558.1 
Ptprz1 Protein tyrosine phosphatase receptor Z1 NM_001170685.1 
Cspg4 Chondroitin sulfate proteoglycan 4 NM_031022.1 
Bcan Brevican NM_001033665.1 
Sema3a Semaphorin 3A NM_017310.1  
Nrp1 Neuropilin  NM_145098.2  
EphB1 Eph receptor B1 NM_001104528.1  
Rtn4 Reticulon 4 (Nogo A) NM_031831.1  
Rtn4r Reticulon 4 receptor (Nogo receptor) NM_053613.1  
Ngfr (P75NTR) Nerve growth factor receptor NM_012610.2  
Lingo 1 Leucine rich repeat and Ig domain containing 1  NM_001100722.1 
Mag Myelin associated glycoprotein NM_017190.4  
Mog Oligodendrocyte glycoprotein NM_022668.2  
PirB  Paired Ig-like-receptor B XM_001076302.2 
   
Table 4. Genes promoting axonal sprouting (A) and sprouting inhibitors (B) included in the 
TaqMan® array analysis presented by the NCBI reference sequence, name and abbreviation.  
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The spatial and temporal dynamics of cerebral micro-vascular rearrangement after stroke are 
also closely related to neurological recovery. In a human post-mortem study sprouting 
angiogenesis was documented 5-92 days after stroke in the penumbra region (Krupinski et 
al., 1994). Scanning electron microscopic study of animal stroke models demonstrated, that 
radially arranged neocortical arterioles and small veins lost their regular patterns within one 
day of occlusion, and soon afterwards started to form a very dense network of anastomosing 
micro-vessels (Krupinski et al., 2003). 
Compromised brain circulation activates complex processes that could facilitate the 
restoration of blood flow in the penumbra region. The low oxygen level prompts early 
response by activating oxygen responsive molecules, cytokines and other inflammatory 
factors (Table 5) (Beck and Plate, 2009). HIF-1a, the main regulator activates a series of 
genes responsible for metabolic changes in the penumbra, vasomotor tone and angiogenesis. 
Angiogenesis (sprouting or splitting and proliferating of endothelial cells in the preexisting 
blood vessel), vasculogenesis (de novo vessel growth) and arteriogenesis (transforming of 
small arteries into larger conducting arteries) result in neovascularization of the affected brain 
territory (Risau, 1997). 
Table 5. Genes promoting microvascular remodeling included in the TaqMan® array 
analysis presented by the NCBI reference sequence, name and abbreviation. 
 
Table 5 Genes regulating microvascular remodeling  
Abbreviation Name 
NCBI Reference 
Sequence 
Vegfa Vascular endothelial growth factor a NM_001110333.1 
Kdr Kinase insert domain receptor NM_013062.1 
Flt1 FMS-related tyrosine kinase NM_019306.1 
Egfr Epidermal growth factor receptor NM_031507.1 
Ngf Nerve growth factor (beta polypeptide)  XM_227525.5 
Bdnf Brain derived neurotrophic factor NM_012513.3 
Igf1 Insulin-like growth factor 1 NM_001082477.2 
Igfbp6 Insulin-like growth factor binding protein 6 NM_013104.2 
Hif1a Hypoxia inducible factor 1, alpha subunit NM_024359.1 
Notch 1 Notch 1 NM_001105721.1 
Jag1 Jagged 1 NM_019147.1 
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 The reperfusion-mediated injury of the blood–brain barrier (BBB) is an important 
mechanism of the transformation from ischemic to hemorrhagic stroke. In addition to 
hemorrhage, a subset of patients do not improve after successful recanalization despite 
restored cerebral circulation (Dalkara and Arsava, 2012). Reperfusion injury is defined as a 
biochemical cascade causing a deterioration of ischemic brain tissue that parallels and 
antagonizes the beneficial effect of recanalization (Yang and Betz, 1994). 
 
Figure 4. Schematic model of neurovascular mechanism of post-ischemic reperfusion injury. 
During reperfusion after ischemia, overproduction of reactive oxygen species (ROS) causes 
oxidative stress. The oxidative stress damages the endothelial cells, resulting in an exposure 
of the sub-endothelial extracellular matrix to blood flow. The exposure triggers adhesion and 
activation of platelets in microvasculature causing thrombosis. The injured endothelial cells 
release metalloproteinase that attacks basal lamina causing leakage of the blood–brain barrier 
(BBB)(Bai and Lyden, 2015). 
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Table 6. Genes involved in the development of reperfusion injury included in the TaqMan® 
array analysis presented by the NCBI reference sequence, name and abbreviation. 
During post-ischemic reperfusion in a focal transient MCAO rat model, BBB disruption is 
typically observed to be more severe than when compared with permanent MCAO. 
Furthermore, increased cerebral blood flow volume during reperfusion is correlated to 
worsened BBB disruption (Yang and Betz, 1994). Post-ischemic reperfusion causes 
enhanced production of free radicals and release of proteases from endothelial cells, 
astrocytes, microglia, and neurons. The matrix metalloproteinases (MMPs) play a major role 
mediating attack on the basal lamina in cerebral capillaries (Yang et al., 2007). 
Table 6 Genes involved in oxidative stress and reperfusion injury  
Abbreviation Name 
NCBI Reference 
Sequence 
Cxcl 12 Chemokine (C-X-C motif) ligand 12  NM_001033882.1 
IL1ᵦ Interleukin 1 beta NM_031512.2 
CXCL8 C-X-C motif ligand 8 NM_000584.3 
Tnf Tumor necrosis factor NM_012675.3 
Icam1 Intercellular adhesion molecule 1 NM_012967.1 
Vcam1 Vascular cell adhesion molecule NM_012889.1 
Sele Selecin E NM_138879.1 
TGFᵦ 1 Transforming growth factor, beta 1 NM_021578.2 
Infg Interferon gamma NM_138880.2 
Sod1 Superoxide dismutase 1 NM_017050.1 
Sod2 Superoxide dismutase 2 NM_017051.2 
Stat3 Signal transducer and activator of transcription NM_012747.2 
Csnk2b Casein kinase 2 beta NM_001035238.2 
Cybb Cytochrom b-245, beta polypeptide NM_023965.1 
Rac1 Ras-related botulinum toxin substrate 1 NM_134366.1 
Gpx1 Glutathion peroxidase 1 NM_030826.3 
Cat Catalase NM_012520.1 
Mmp9 Matrix metalloproteinase 9 NM_031055.1 
Mmp2 Matrix metalloproteinase 2 NM_031054.2 
Mmp12 Matrix metalloproteinase 12 NM_053963.2 
TIMP1 Tissue inhibitor of metalloproteinase 1 NM_053819.1 
TIMP2 Tissue inhibitor of metalloproteinase 2 NM_021989.2 
TIMP3 Tissue inhibitor of metalloproteinase 3 NM_012886.2 
TIMP4 Tissue inhibitor of metalloproteinase 4 NM_001109393.1 
Lrp1  LDL receptor related protein 1 NM_001130490.1 
Plat Plasminogen activator, tissue type NM_013151.2 
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The core of brain tissue exposed to the most dramatic blood flow reduction is fatally injured 
and subsequently undergoes necrotic cell death within minutes of a focal ischemic stroke. A 
zone of less severely affected tissue around the necrotic core, also called as the “ischemic 
penumbra” is rendered functionally silent by reduced blood flow but remains metabolically 
active (Ginsberg, 1997). Many neurons in the penumbra region may undergo apoptosis after 
several hours or days, and thus they are potentially recoverable for some time after the onset 
of stroke. Apoptosis can be initiated by internal events (ie, “Intrinsic Pathway”) (Fig. 5.) 
involving the disruption of mitochondria and the release of the cytochrome C, or  
alternatively, cell surface receptors can be activated by specific ligands that bind to “death 
receptors” (ie, “Extrinsic Pathway”) (Fig. 6.) (Table 7A). 
Figure 5. Intrinsic signaling of apoptosis in cerebral ischemia (Broughton et al., 2009) 
Cerebral ischemia elevates cytosolic calcium levels through the stimulation by glutamate of 
N-methyl-D-aspartate (NMDA) or D,L-α-amino-3-hydroxy-5-methyl-isoxazolpropionic 
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acid (AMPA) receptors, or by the activation of acid-sensing ion channels (ASICs) . Increased 
intracellular calcium activates calpains and mediates cleavage of Bid to truncated Bid (tBid) 
initiating the intrinsic signaling cascade of apoptosis. At the mitochondrial membrane tBid 
interacts with apoptotic proteins such as Bad and Bax, which is typically neutralized by 
antiapoptotic B-cell leukemia/lymphoma 2 (Bcl-2) family proteins Bcl-2 or Bcl-xL. After 
heterodimerization of proapoptotic proteins with tBid, mitochondrial transition pores (MTP) 
are opened, thus releasing cytochrome c (Cytc) or apoptosis-inducing factor (AIF). Once 
released into the cytosol, Cytc binds with apoptotic protein-activating factor-1 (Apaf-1) and 
procaspase-9 to form an “apoptosome,” which activates caspase-9 and subsequently caspase-
3. Activated caspase-3 cleaves nDNA repair enzymes, such as poly (ADP-ribose) polymerase 
(PARP), which leads to nDNA damage and apoptosis. By contrast, AIF translocates rapidly 
to the nucleus where it mediates large-scale DNA fragmentation and cell death in a caspase-
independent manner. In addition, nuclear pathways of neuronal apoptosis are activated in 
response to DNA damage, for example, through phosphorylation and activation of p53. 
Furthermore, cerebral ischemia and reperfusion generate superoxide anions (O2−), which 
causes DNA damage (Broughton et al., 2009). 
Extrinsic mechanisms of apoptosis involve the engagement of death receptors located on the 
plasma membrane and is hence also referred as the “death receptor pathway”. Cell surface 
death receptors belong to the tumor necrosis factor receptor (TNFR) superfamily, and include 
TNFR-1, Fas, and p75NTR.Forkhead1, a member of the forkhead family of transcription 
factors, stimulates expression of target genes, such as the Fas ligand (FasL) (Sugawara et al., 
2004). The extracellular FasL binds to Fas death receptors (FasR), which triggers the 
recruitment of the Fas-associated death domain protein (FADD). FADD binds to procaspase-
8 to create a death-inducing signaling complex (DISC), which activates caspase-8. Activated 
caspase-8 either mediates cleavage of Bid to truncated Bid (tBid), which integrates the 
different death pathways at the mitochondrial checkpoint of apoptosis, or directly activates 
caspase-3. At the mitochondrial membrane tBid interacts with Bax, which is usually 
neutralized by antiapoptotic B-cell leukemia/lymphoma 2 (Bcl-2) family proteins Bcl-2 or 
Bcl-xL. Dimerization of tBid and Bax leads to the opening of mitochondrial transition pores 
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(MTP), thereby releasing cytochrome c (Cytc), which execute caspase 3-dependent cell death 
(Broughton et al., 2009). 
 
Figure 6. Extrinsic signaling of apoptosis after cerebral ischemia (Broughton et al., 2009) 
Interactions between the pro-apoptotic and anti-apoptotic Bcl-2 family proteins on the outer 
mitochondrial membrane are believed to play an important role in cell survival (Love, 2003). 
Typically, anti-apoptotic members (Table 7B) are located on the outer membrane and 
suppress apoptosis through multiple mechanisms, including conserving mitochondrial 
membrane potential, inhibiting the release of apoptotic proteins, stabilizing the mitochondrial 
transition pores, thus preventing its opening, and controlling the activation of caspase 
proteases (Webster et al., 2006). 
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Table 7. Pro-apoptotic (A) and anti-apoptotic (B) genes included in the TaqMan® array 
analysis presented by the NCBI reference sequence, name and abbreviation. 
 
Table 7A Pro-apoptotic genes 
Abbreviation Name 
NCBI Reference 
Sequence 
Bax Bcl2-associated X NM_017059.1 
Bid BH3 interacting domain death agonist NM_022684.1 
Casp1 Caspase 1 NM_012762.2 
Casp2 Caspase 2 NM_022522.2 
Casp3 Caspase 3 NM_012922.2 
Casp6 Caspase 6 NM_031775.2 
Casp7 Caspase 7 NM_022260.2 
Casp8ap2 Caspase 8 associated protein 2 NM_001107921.1  
Casp9 Caspase 9 NM_031632.1 
Card 10 Caspase recruitment domain family NM_001130554.1 
Bcl2/11 Bcl2 like 11 transcript variant 1 NM_022612.1 
Fadd Fas associated via death domain NM_152937.2 
Apaf1 Apoptotic peptidase activating factor 1 NM_023979.1 
Diablo Diablo, IAP-binding mitochondrial protein NM_001008292.1  
Cycs Cytochrome c  NM_012839.2 
Bcl3 B-cell CLL/lymphoma 3 NM_001109422.1 
Pidd1 P53-induced death domain protein 1 NM_001106318.2 
Cradd 
CASP2 and RIPK1 domain containing adaptor 
with death domain  
NM_001108085.1 
Table 7B Anti-apoptotic genes 
Abbreviation Name 
NCBI Reference 
Sequence 
Proc Protein c NM_012803.1 
Hspa1a Heat shock 70kD protein 1A NM_031971.2 
Procr Protein c receptor NM_001025733.2 
Fr2 Coagulation factor II receptor NM_012950.2 
Xiap X-linked inhibitor of apoptosis NM_022231.2 
Ikbkg 
Inhibitor of kappa light peptide gene enhancer 
in b-cells, kinase gamma 
NM_199103.1 
Nkap NFKB activating protein NM_001024872.1 
Birc3 Baculovira IAP repeat containing 3 NM_023987.2 
Naip NLR family apoptosis inhibitor protein XM_226742.4 
Bcl2l2 Bcl2-like 2 NM_021850.2 
Bcl2l1 Bcl2-like 1 NM_001033671.1 
Ripk1 Receptor interactin serin/threonine kinase 1 NM_001107350.1 
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AIMS: 
Investigation of the molecular background of impaired recovery associated with 
gelatinase inhibition in the subacute phase of ELVO 
 
The matrix metalloproteinase (MMP) 2 and 9 enzymes, also called as gelatinases (Fig. 7A), 
belong to the serine-protease enzyme family, and they are important factors in the 
hemorrhagic transformation of the ischemic brain lesions: they promote blood-brain barrier 
injury, and accelerate cerebral cell death (Asahi et al., 2001; Lee and Lo, 2004). Furthermore 
MMP 9 activity is enhanced by the thrombolytic agent used during reperfusion therapy 
(Burggraf et al., 2007), therefore the inhibition of MMP enzymes could be an ideal adjunctive 
treatment to prevent the hemorrhagic complications.  
Contrary to their deleterious effect on acute lesions, gelatinases may mediate repair 
mechanisms during the delayed phases of stroke recovery. Pharmacological gelatinase 
inhibition 7 days after ischemic brain injury increased lesion size and impaired functional 
regeneration (Zhao et al., 2006). 
Besides their proven interaction with neurovascular remodeling (Zhao et al., 2006), 
gelatinases may influence recovery through interaction with multiple growth promoting and 
inhibitory proteins. Gelatinase activity was demonstrated at the edge of the growth cone of 
dorsal root ganglion neurons (Hayashita-Kinoh et al., 2001), and the expression of 
phosphorylated neurofilament M, a marker for regenerative elongation, was induced by 
MMP9 (Demestre et al., 2004). Axonal re-myelination was also shown to require the 
proteolytic activity of the MMP9 (Oh et al., 1999), while the metalloproteinase mediated 
cleavage of the Reticulon 4 receptor (Rtn4r) was proposed as a potential disinhibitory 
mechanism that could enhance axonal regrowth (Walmsley et al., 2004). The same receptor 
was shown to mediate the astrocytic differentiation of neural progenitor cells, therefore the 
MMP-Rtn4r interaction may also influence the glial scar formation following central nervous 
system injury (Wang et al., 2008). 
The aim of our study was to explore the molecular background of the impaired recovery 
associated with sub-acute metalloproteinase inhibition in ischemic stroke.  
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Investigation of the neuro-restorative action of Selegine in ELVO 
Selegiline (Fig. 7B)  is widely used in the therapy of Parkinson's disease (Tatton et al., 1994). 
Its effectiveness is based on the selective inhibition of monoamine oxidase B (MAO-B) and 
on its anti-apoptotic potential attributed to its ability to eliminate reactive oxygen species and 
stabilize mitochondrial membrane potential (Simon et al., 2005; Szilagyi et al., 2009). 
In in vitro and animal studies our group has demonstrated previously that selegiline attenuates 
apoptosis and decreases infarct size after permanent occlusion of the middle cerebral artery 
(Simon et al., 2001). Furthermore, selegiline attenuated spatial learning deficits following 
focal cerebral ischemia in rats (Puurunen et al., 2001). The clinical use of the administration 
of low dose selegiline in the sub-acute phase of cerebral infarction has also been tested in a 
randomized, double-blinded, clinical pilot study. Although significant functional 
improvement was observed in stroke patients receiving selegiline in combination with 
physiotherapy, the molecular basis underlying this beneficial effect remained unclear 
(Sivenius et al., 2001). As the functional improvements were detected with the therapy being 
initiated days after the onset of stroke, the clinical efficacy was attributed to a potential 
neurorestorative rather than to the previously known neuroprotective properties of the 
molecule. This also means, that the selegiline treatment may potentially benefit those stroke 
patient who could not undergo reperfusion therapy as well.    
To understand the mechanisms how selegiline exerts its actions following focal ischemia, we 
addressed its effects on gene expression. 
 
 
  
Figure 7. The crystal structure of the human Gelatinase B (Matrix Metalloproteinase 9) 
enzyme (A). (Elkins et al., 2002) and the structural formula of the (R) (-) deprenyl 
(Selegiline) molecule (B) (Knoll et al., 1978).  
A B 
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METHODS 
The transient Middle Cerebral Artery Occlusion Model 
 
 
Figure 8. The MCAO filament technique. Schematic diagram displaying the rat carotid 
artery territories and the positioning of the MCAO filament (Longa et al., 1989). 
The experimental model applied in our investigations to model the pathophysiology of 
thrombectomy in intra-cranial ELVO has been used for simulating stroke in rodents for 
decades (Longa et al., 1989). Important to note however, that the abrupt restoration of blood 
flow with the removal of the occluding filament simulate the hemodynamic changes 
associated with mechanical thrombectomy much better, than the hemodynamics of the 
gradual reperfusion occurring during thrombolysis.  
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Adult male CD rats (Charles River, Erkrath, Germany) were housed under controlled 
environmental conditions at an ambient temperature of 22°C with 12h light/dark cycle and 
free access to food and water. Brain ischemia was induced using slightly modified version of 
middle cerebral artery (MCA) filament occlusion model (Longa et al., 1989). Briefly, general 
anesthesia was induced using 5% isofluran in pure O2 at 1 L/min for 4 min in male rats 
weighing 300-350 g. Animals were kept anaesthetized using 2% isoflurane in pure O2 
delivered by snout mask. Animal core (rectal) temperature was maintained constant at 37°C 
using temperature-controlled heat pad. A midline neck incision was made to expose the right 
carotid sheath under the operating microscope (Zeiss, Germany) The common carotid artery 
was isolated with 4-0 silk, and the occipital, pterygopalatine, and external carotid arteries 
were each isolated, cauterized, and divided.  Right MCAO was accomplished by forming a 
small arteriotomy in the external carotid stump, and advancing a 25 mm 4-0 nylon suture 
with a 5 mm cast rubber tip (Doccol, Redlands, CA) through the arteriotomy into the internal 
carotid artery until the tip occluded the MCA (Fig 8.). To ensure adequate levels of cerebral 
ischemia, transcranial measurements of cerebral blood flow (CBF) were made over the MCA 
territory using Laser-Doppler Flowmetry (Perimed Inc., Stockholm, Sweden). Placement of 
the suture was confirmed by reduction of LDF readings to at least 40% of baseline (Fig. 9.). 
After 60 min of ischemia, animals were re-anesthetized and the occluding suture was 
removed.  
 
Figure 9. Trans-cranial measurements of the blood flow during tMCAO show a sudden drop 
in the cerebral perfusion at the time of the insertion of the occluding filament. (A). TTC 
staining of the native coronal brain section at bregma level delineates the ischemic lesion (*) 
by the lack of red staining of the viable mitochondria (B). 
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Stereotactic delivery of gelatinase inhibitor 
 
 
 
Figure 10. Stereotaxic injection for the delivery of the gelatinase inhibitor, rat specific 
coordinates: 0.8 mm caudal to Bregma, lateral: 1.6 mm to midline; depth: 4.1 mm to skull 
surface (A). Coronal section of a native rat brain demonstrating the successful stereotactic 
injection of Evans Blue dye into the right lateral ventricle (B). 
 
Due to the excessive amount of inhibitor necessary for achieving sufficient gelatinase 
inhibitions intra-cranially with the currently available semi-selective compounds during 
systemic administration, we have decided to apply intra-cranial drug delivery using a 
dedicated stereotactic device. We performed pilot experiments on similar size rats (n=3) to 
ensure the adequate calibration of the stereotactic device (Harvard Apparatus, Boston, MA) 
using Evans Blue dye before applying the inhibitor treatments (Fig 10.) Finally 7 days after 
the tMCAO, we injected 20 µl of FN-439 metalloproteinase inhibitor (0.59 mg/kg, 720 mM 
in saline) or saline, into their right lateral ventricle of the animals over 20 min, using the 
previously calibrated stereotaxic injector  under general anesthesia. 
Administration of selegiline treatment 
Selegiline treatment was started 48 hours following the initiation of the 60 min tMCAO. 
Animals in the treatment arm (n=6-6) were infused with 0.2 mg/kg/day of selegiline in a 
vehicle of 0.9% physiological saline, delivered via implantable osmotic pumps (Alzet, 
ALZA, Palo Alto, CA) placed intra-peritoneal for seven days (Fig. 11). Control rats (n=6-6) 
were infused with the vehicle only. The pumps were placed in the abdominal cavity under 
short general anesthesia. The rats were sacrificed after 7 days of treatment.  
B A 
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Figure 11. Experimental protocol of selegiline treatment. Continuous infusions were 
initiated 48 hours after MCAO. The animals underwent MRI investigation 24h before 
sacrifice. 
Quantification of brain edema 
Magnetic resonance imaging (MRI) study was performed on a 1.5 Tesla Philips Achieva 
clinical scanner using a SENSE-Flex-M coil 6 days after the initiation of treatment. After 
being anaesthetized with a bolus of ketamine/xilazin cocktail, animals were placed in supine 
position inside the clinical MRI scanner, and brain edema was visualized with a T2 weighted 
3D VISTA sequence (Field of view: (AP/RL/FH) 60/60/45 mm, Voxel size: 0.6/0.6/1.2 mm, 
Reconstruction matrix = 128, number of slices =75, Echo time was set to the shortest 
possible, which resulted in TE=301 ms. Flip angle =90°; TR=2250 ms, NSA=5).  
The obtained images were contrast enhanced to better differentiate edema from the 
background. Subsequently, planimetric measurements were performed on the coronal 
sections 7 mm posterior to the frontal pole using Image J software (NIH, Bethesda, USA). 
Animals with extensive cortical infarctions, potentially caused by failed reperfusion (1 
animal in each group) were excluded from the statistical analysis. 
The Animal Examination Ethical Council of the Animal Protection Advisory Board at the 
Semmelweis University, Budapest specifically approved these studies. Thus, the procedures 
involving rats were carried out according to experimental protocols that meet the guidelines 
of the Animal Hygiene and Food Control Department, Ministry of Agriculture, Hungary, 
which is in accordance with EU Directive 2010/63/EU for animal experiments EU Directive 
2010/63/EU for animal experiments.  
The animal experiments were carried out at the Experimental laboratory of the Heart and 
Vascular Center of Semmelweis University, and the imaging studies were done at the MRI 
Unit of the Heart and Vascular Center.   
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Tissue sampling and mRNA extraction for the TaqMan® array analysis  
Nine days after the tMCAO, the animals were decapitated and their brains were rapidly 
removed. Coronal sections (12 m thick) were cut from the native brain tissue using a rat 
brain matrix (Harvard Apparatus, Boston, USA) starting 6 mm caudal to the frontal pole. 
Tetraphenyl-tetrazolium chloride (TTC) staining was performed on the first coronal sections 
(6-8 mm from the frontal pole of the brain) to identify the lesion. After 15 min of incubation 
at 37°C, 3 samples of brain tissue from the border of the ischemic lesion were dissected using 
a 2 mm diameter punch biopsy needle.  Total RNA was extracted with TRIzol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. The extracted RNA 
was quantified using UV spectrophotometry; only samples with a 260:280 ratio greater than 
1.7 were further processed (Fig 12.). RNA was reverse transcribed in duplicates using 
Omniscript kit (Qiagen, Valencia, CA). A third RNA sample was incubated without reverse 
transcriptase as a no-RT control.  
 
Figure 12.  UV spectrophotometry analysis of a good quality total RNA sample with a 
28s/18s RNA ratio > 1,7.  
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TaqMan® array analysis 
Samples were run parallel on a custom designed TaqMan® gene expression array containing 
probes for 84 representative genes involved in axonal sprouting, apoptosis regulation, 
reperfusion injury and neurovascular remodeling based on literature data (See Table 4-7).  
Gene expressional values were compared between the treatment and control groups after 
being normalized to a previously established housekeeping control (Psmc4-
Rn00821605_g1). Initially 4 housekeeping controls were tested, and the one with the most 
table expression pattern was chosen for reference. We have only evaluated those probes in 
the final analysis, that were adequately functioning in both parallel samples of all included 
subjects (n=5+5 for the gelatinase inhibitor and n=6+6 for selegiline respectively).  
RNA isolation and Real-Time Quantitative PCR measurement was performed by UD-
GenoMed Medical Genomic Technologies Ltd (Debrecen, Hungary). 
 
 
Figure 13. Schematic of the TaqMan principle. Polymerization catalyzed by the Taq enzyme 
proceeds as typical for a PCR reaction using forward and reverse primers. Allele-specific 
fluorogenic probes, 5′ labeled with a reporter dye and 3′ labeled with a quencher dye, 
hybridize to complementary templates (1-2). Proximity of the two dyes allows the quencher 
dye to absorb the emission of the reporter dye. During polymerization, the Taq enzyme 
displaces and cleaves hybridized probes (3-4), producing an exponential increase in cleaved 
reporter dye emission. TaqMan probes were named after the videogame Pac-
Man (Taq Polymerase + PacMan = TaqMan) as its mechanism is based on the Pac-Man 
principle (Yuan et al., 2000).  
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In situ gelatin zymography 
Successful inhibition of the MMP activity was demonstrated by in situ gelatin zymography. 
The frontal part of the brain was cut into 20µm thick slices, and the samples were incubated 
overnight at 37°C with 40µl/ml DQ gelatin-FITC (Molecular Probes, Eugene, OR) (Amantea 
et al., 2008). After washing away the excess gelatin, the slides were cover slipped. 5 fields 
of view were captured in the peri-infarct cortex through a fluorescent microscope (Zeiss, 
Germany) to be analyzed with the Image J software (NIH, Bethesda, DC).  
Antibody selection and tissue preparation for immunolabeling 
The information gathered from our array analysis largely resembles of looking for something 
very small in a large mist at night using a very dime flashlight. Some silhouettes can be made 
out, but further definition of the objects is definitely needed by another modality. 
Immunolabeling, if feasible, is a very reliable method for confirming our initial findings and 
to localize the protein end-products of the upregulated genes. However the considerable 
damage to the brain tissue make this technic challenging in the context of experimental 
stroke, therefore we have limited the use of this rather time consuming modality to study the 
most relevant gene expressional changes found in our array experiments. We have performed 
immunolabeling for the intracellular domain of Notch1 (NICD), Jagged 1 and we used (rat 
endothelial cell antigen) RECA antibodies to analyze micro-vessel density in the Selegiline 
study. In the MMP inhibitor experiments we applied the Reticulon 4 receptor (Rtn4r) 
antibody. We also performed double-labeling using standard cellular markers. (See below). 
 After several attempts to optimize the quality of the labeling, we have decided to process 
our samples as free floating brain section. 9 days after the MCAO procedure rats were deeply 
anesthetized and perfused trans-cordially with 150 ml saline followed by 300 ml 4% 
paraformaldehyde prepared in phosphate buffer (PB; pH=7.4). Brains were removed and 
postfixed in 4% paraformaldehyde for 24 h and then transferred to PB containing 20% 
sucrose for 2 days. Serial coronal brain sections were cut at 40 m on a cryostat between 4.0 
and -6.0 mm bregma levels. Subsequently, the samples were processed for 
immunohistochemistry. 
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Immunolabeling for Rtn4r  
Every fourth free-floating brain section of MCAO-treated animals were immune-stained with 
antisera raised against Rtn4r (1:300, Abcam, Cambridge, MA; cat. number: ab 26291). The 
specificity of the labeling is suggested by single bands in western blot experiments provided 
by the manufacturer. 
The sections were pretreated with pH6 citrate buffer at 70°C for 60 minutes, followed by 3% 
hydrogen peroxide for 15 min and 1% bovine serum albumin in PB containing 0.5% Triton 
X-100 for 30 min at room temperature. Then, the antisera (1:300) was applied for 48 h at 
room temperature followed by incubation of the sections in biotinylated donkey anti-rabbit 
secondary antibody (1:1000; Vector Laboratories, Burlingame, CA) and then in avidin-
biotin-peroxidase complex (1:500; Vector Laboratories) for 1 h. Subsequently, the labeling 
was visualized by incubation in 0.02% 3,3-diaminobenzidine (DAB; Sigma-Aldrich, St. 
Louis, MI), 0.08% nickel (II) sulfate and 0.001% hydrogen peroxide in PB, for 5 min. 
Sections were mounted, dehydrated and coverslipped with Cytoseal 60 (Stephens Scientific, 
Riverdale, CA). 
Double immunolabeling of Rtn4r with cell markers  
The following antisera were used as cellular markers in double labeling experiments: mouse 
anti-NeuN as a marker of neuronal nuclei (1∶500; Millipore, Billerica, MA, cat. number: 
MAB377), mouse anti-S-100, as a marker of astrocytes (1∶5000 Sigma-Aldrich, St. Louis, 
MI cat. number: S2532), rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1) as a 
marker of microglial cells (1:1000; Wako, Japan; cat. number: 019-197419), and rabbit anti-
Von Willebrand factor (vWF) as an endothelial marker (1∶1500 Abcam,Cambridge, MI; cat. 
number: ab6994). 
First, free-floating sections of the 6 rats used for single labeling Rtn4r were immune-labeled 
for this protein, as described above, except that donkey anti-mouse secondary antibodies, 
cross-absorbed with IgG of several different species (including rabbit) were used to avoid 
cross-reactions (1:1000 dilution; Jackson ImmunoResearch, West Grove, CA). Another 
difference was that the labeling was visualized using fluorescein isothiocyanate-tyramide 
(1:8000) and H2O2 in Tris hydrochloride buffer (0.1 M, pH=8.0) for 6 min instead of DAB. 
Then, the sections intended for double labeling with Iba1 and vWF were incubated in citric 
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acid buffer (pH=6.0) for 30 min to remove rabbit antibodies from the sections in order to 
avoid cross reactions. Subsequently, all sections were placed in antibodies of the above 
described cell markers for 48 h at room temperature. The sections were then incubated in 
Alexa594 donkey anti-mouse (or anti-rabbit for Iba1) secondary antibody (1:500; Molecular 
Probes, Eugene, OR) for 2 h, washed in PB overnight, mounted and cover slipped in anti-
fade medium (Prolong Antifade Kit, Molecular Probes, Eugene, OR). 
Immunolabeling of Notch 1 intracellular domain (NICD), and Jagged 1 and RECA 
Every fourth free-floating brain section of MCAO-treated animals were immune-stained with 
antisera raised against NICD (ABCAM, Cambridge; cat. number: ab52301), Jagged 1 
(LifeSpan BioSciences, Seattle, WA, USA; cat. number: LS-C18929) and RECA (ABCAM, 
Cambridge, MA, USA; cat. number: ab9774). The specificity of the labeling is suggested by 
single bands in western blot experiments provided by the manufacturer. 
The sections were pretreated with 3% hydrogen peroxide for 15 min followed by 1% bovine 
serum albumin in PB containing 0.5% Triton X-100 for 30 min at room temperature. Then, 
the antisera (1:1000 for RECA, 1:500 for NICD, and 1:100 for Jagged 1) were applied for 48 
h at room temperature followed by incubation of the sections in biotinylated donkey anti-
rabbit (or anti-mouse for RECA) secondary antibody (1:1000; Vector Laboratories, 
Burlingame, CA) and then in avidin-biotin-peroxidase complex (1:500; Vector Laboratories) 
for 1 h. Subsequently, the labeling was visualized by incubation in 0.02% 3,3-
diaminobenzidine (DAB; Sigma), 0.08% nickel (II) sulfate and 0.001% hydrogen peroxide 
in PB, for 5 min. Sections were mounted, dehydrated and coverslipped with Cytoseal 60 
(Stephens Scientific, Riverdale, NJ). 
Double immunolabeling of NICD and Jagged 1 with cell markers  
The following antisera were used as cellular markers in double labeling experiments: mouse 
anti-synaptophysin as a marker of neuronal presynaptic terminals (1:1000; DAKO, Ely, UK; 
cat. number SY38), mouse anti-glial fibrillary acidic protein (GFAP) as a marker of 
astrocytes (1:300; Santa Cruz Biotechnology, Delaware, CA, USA; cat. number: sc-33673), 
rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1) as a marker of microglial cells 
(1:1000; Wako, Japan; cat. number: 019-197419) and mouse anti-RECA for endothelium 
(1:1000, ABCAM, Cambridge, MA, USA; cat. number: ab9774). 
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First, free-floating sections of the 12 rats used for single labeling NICD and Jagged 1 were 
immunolabeled for these proteins, as described above, except that donkey anti-mouse 
secondary antibodies, cross-absorbed with IgG of several different species (including rabbit) 
were used to avoid cross-reactions (1:1000 dilution; Jackson ImmunoResearch, West Grove, 
PA). Another difference was that the labeling was visualized using fluorescein 
isothiocyanate-tyramide (1:8000) and H2O2 in Tris hydrochloride buffer (0.1 M, pH=8.0) for 
6 min instead of DAB. Then, the sections intended for double labeling with Iba1 were 
incubated in citric acid buffer (pH=6.0) for 30 min to remove rabbit antibodies from the 
sections in order to avoid cross reactions. Subsequently, all sections were placed in antibodies 
of the above described cell markers for 48 h at room temperature. The sections were then 
incubated in Alexa594 donkey anti-mouse (or anti-rabbit for Iba1) secondary antibody 
(1:500; Molecular Probes, Eugene, OR) for 2 h, washed in PB overnight, mounted and cover 
slipped in anti-fade medium (Prolong Antifade Kit, Molecular Probes). 
Microscopy, photography and image processing and quantification 
Sections were examined using an Olympus BX60 light microscope. Coronal sections 
obtained near bregma level were involved in the analysis from each animal (6 brains per 
group). After identification of the infarcted region 5 adjacent fields near the lesion were 
captured in the striatum at 2048 X 2048 pixel resolution with a SPOT Xplorer digital CCD 
camera (Diagnostic Instruments, Sterling Heights, MI) using 40 X objectives. The digitized 
images were then contrast enhanced (equally), and a thresholding procedure was used to 
determine the proportion of immune-reactive area within the peri-ischemic region with 
Image J software (NIH, Bethesda, USA). The data are presented as a percentage of positive 
immunoreactivity area within the captured images. 
 Confocal images were acquired with a Nikon Eclipse E800 confocal microscope equipped 
with a BioRad Radiance 2100 Laser Scanning System using a 60 X objective at an optical 
thickness of 2 µm. A section containing lesion at the level of the anterior commissure was 
randomly selected from the double labeled brains for each marker. The total number of 
NICD-, Jagged 1- and Rtn4r-ir cells with an identifiable cell nucleus as well as the number 
of double labeled cells was counted. 
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Western blot for Rtn4r 
In order to improve the quantification of the protein end-product Western blot analysis was 
performed on basis of the significant mRNA expression change of the Rtn4r gene. We used 
NuPAGE 4-12% bistris gels (Invitrogen, Gent, Belgium), proteins were transferred to 
polyvinylidene-fluoride membranes, which were blocked by Tris-buffered saline/0.1% 
Tween-20 containing 5% dried milk powder followed by incubation in the same buffer 
containing the appropriate primary antibody (1:500, Anti-Rtn4 Receptor, cat. number: AF 
12080, and Anti-GAPDH, cat. Number: AF 5718, R&D, Minneapolis, MI). Membranes were 
washed in TBST and incubated with the appropriate peroxidase-conjugated secondary 
antibody. Reactions were developed using HRP, and quantification was performed using the 
Image lab 4.0.1. software (Bio-Rad Laboratories,  Hercules, CA), results were analyzed after 
normalization with the GAPDH control. 
Statistical analysis 
Normalized c-DNA expression values, and normalized protein levels were used for analysis.  
We used Student T test for screening calculations, and Mann-Whitney-Wilcoxon (MWW) 
test for confirming our result in the Graphpad Prism 6 software (Graphpad Software, La Jolla, 
CA). 
We have not used power analysis in the planning of our experiments. While nobody contests 
the usefulness of power analysis in general, many more questions have been raised in the 
accuracy of these calculations in the setting of exploratory gene expression studies. The used 
algorithms can become very complex in this context, taking the multiple interactions among 
genes into account.  While literature data clearly show that stable array results are typically 
not obtained until at least five biological replicates have been used, sample sizes of 5/ group 
usually provide sufficient power, especially in well standardized protocols using inbreed 
laboratory animals  (Pavlidis et al., 2003). Our most important goal was to maximize the 
homogeneity of the experiments when we decided to limit the number of animals to 6 in each 
treatment group. This sample size allowed us to carry out all experiments on the same day 
to maximally reduce the baseline variance of gene expression occurring over time among the 
individual subjects.  
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RESULTS 
Changes of mRNA expression in the peri-infarct cortex following delayed gelatinase 
inhibition 
Figure 14. Graphic (A) and numerical display of mRNA expression changes induced by 
gelatinase inhibition in the delayed phase of focal ischemia. The p values are calculated by 
T-test. Result show the classical volcano plot distribution with obvious induction of one gene 
(Rtn4 r /red dot) and borderline expressional changes of 3 others (Dcc, C-Jun, Ngf/gray dots) 
(Nardai et al., 2016). 
 
Gene 
Fold 
change 
P 
value 
Gene 
Fold 
change 
P 
value 
Gene 
Fold 
change 
P 
value 
Gene 
Fold 
change 
P 
value 
GAP43 1,13 0,46 Cspg4 0,91 0,47 Birc3 0,86 0,19 Bcl3 0,85 0,51 
Jun 1,30 0,04 Nrp1 1,05 0,82 Naip2 1,64 0,26 Card10 1,03 0,71 
SPRR1a 1,16 0,39 Rtn4 1,13 0,43 Bcl2l2 0,94 0,65 Cradd 0,90 0,31 
Neurod6 1,04 0,88 Rtn4r 1,69 0,02 Bcl2l1 0,90 0,45 Sod1 1,17 0,21 
Tuba1a 1,17 0,14 Ngfr 2,03 0,06 Ripk1 0,98 0,86 Sod2 0,95 0,70 
L1cam 0,99 0,95 Mag 0,82 0,27 Bax 1,02 0,78 Stat3 0,96 0,75 
Marcks 1,03 0,76 Mog 1,25 0,13 Bid 1,15 0,41 Csnk2b 0,93 0,28 
Cuzd1 1,56 0,52 Lilrb3 0,22 0,16 Casp1 0,93 0,75 Cybb 0,54 0,26 
Nefm 1,18 0,33 Notch1 1,11 0,20 Casp2 1,00 0,98 Gpx1 0,97 0,88 
DCC 0,67 0.05 Jag1 1,14 0,34 Casp3 1,00 0,98 Cat 0,89 0,28 
Igf1 1,43 0,48 Tnf 0,70 0,27 Casp6 0,85 0,35 Hif1a 0,93 0,39 
Igfbp6 0,95 0,90 Icam1 0,77 0,18 Casp7 0,83 0,09 Mmmp9 0,67 0,22 
Cxcl12 1,56 0,40 Vcam1 1,07 0,48 Casp8 0,87 0,25 Plat 1,07 0,46 
Vegfa 1,07 0,52 Sele 0,65 0,13 Casp9 1,03 0,64 Timp1 0,81 0,44 
Kdr 0,94 0,78 Tgfb1 0,91 0,71 Casp12 0,71 0,31 Timp2 0,96 0,74 
Flt1 1,05 0,65 Infg 0,75 0,67 BCL2l11 0,78 0,38 Timp3 1,00 0,99 
Ngf 1,13 0,58 Hspa1a 1,58 0,15 Fadd 0,92 0,39 Timp4 1,11 0,40 
Bdnf 1,12 0,76 Procr 1,39 0,31 Apaf1 1,15 0,28 Mmp2 0,59 0,12 
Ncan 1,02 0,90 F2r 1,00 0,99 Diablo 1,12 0,21 Mmp12 0,36 0,15 
Ptprz1 1,12 0,42 Xiap 0.89 0,32 Cycs 1,03 0,78    
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Prior to the mRNA analysis, the in situ zymography of our samples demonstrated a mean 
81% decrease of the gelatinase activity in the peri-infarct cortical regions of the treatment 
animals compared to the controls (p=0,008) following the intra-cerebroventricular injection 
of the FN-439 inhibitor (Fig. 15), similarly to previously published data. 
 
Figure 15. Gelatinase activity in the peri-infarct cortex. Gray lines indicate the border of the 
lesion. The distribution of the fluorescence signal following the gelatinase inhibition (B) is 
similar to the non-treated controls (A), but the number and size of the spot is clearly 
decreased. The columns on the right (C) show the quantification of the immunofluorescence 
signal intensity. Error bars represent SEM (Nardai et al., 2016).  
The successfully tested 84 genes involved in synaptic plasticity, apoptosis regulation, 
reperfusion injury, and neurovascular remodeling (Fig. 14) could be regrouped into three 
categories based on their response to the delayed (day 7) gelatinase inhibition. The vast 
majority of the tested mRNAs (n=80) showed unaltered expression, while the Reticulon 4 
receptor (Rtn4r) was clearly induced in the cortex of the treated animals (Fold change: 1,69, 
p=0,015 by T-test, p=0,028 by MWW test) (Fig. 16.). We found altered expression with 
borderline statistical significance in three additional genes: the expression of the C-jun 
protooncogene (Jun)showed a 30% increase (p=0.040 by the T-test, p=0.075 by MWW),the 
Nerve growth factor receptor (Ngfr) showed a mean 2,03 fold increase (p=0.064 on the T-
test, p=0.032 by MWW), while the mRNA level of the Deleted in colorectal carcinoma 
(DCC) axonal guidance receptor was decreased by 33% (p=0.051 on the T-test, p=0.008 by 
MWW) compared to the untreated controls (Fig. 14).   
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Rtn4r protein expression following MCAO and its alteration by gelatinase inhibition 
Rtn4r immunoreactivity under normal conditions is unevenly distributed in the intact brain 
tissue both in the striatum and the cerebral cortex [15]. Following MCAO, Rtn4r appears in 
the peri-infarct region around the lesion without any labeling within the lesion (Fig. 16A). In 
fact, the border of the lesion can be defined clearly based on the Rtn4r histochemistry. The 
labeling in the peri-infarct region is present in cell bodies. Following Fn439 treatment, the 
distribution of Rtn4r labeling did not change as compared to control MCAO (Fig. 16B), 
however the intensity of the immunolabeling was markedly elevated in the peri-infarct 
region.  
 
Figure 16. Rtn4r immunoreactivities in the peri-infarct region of the cerebral cortex. A: 
Rtn4r labeling is elevated in the peri-infarct region, the appearance of labeling indicates the 
border of the lesion. B: The distribution of Rtn4r following gelatinase inhibitor treatment is 
similar to that of non-treated MCAO but an increased intensity of Rtn4r labeling is in 
response to the FN439 treatment. Star symbols (*) indicate the lesioned areas. Scale bar = 
500 µm (Nardai et al., 2016). 
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Confirmation of the increased Rtn4r protein abundancy by Western Blot 
In order to better quantify the Rtn4r protein expression in the peri-infarct cortex, we have 
performed western blotting analysis of the native brain samples. The blots have also 
confirmed the increased protein level for the Rtn4 receptor (p= 0,004) in the treated animals 
(Fig 17B). 
   
 
Figure 17.  Box and whiskers show the relative mRNA (A) and protein (B) expression level 
of the Rtn4r in the peri-infarct cortex following delayed (day 7) gelatinase inhibitor 
treatment. P-values were calculated by T-test. Insert show the original blot image. Error bars 
represent minimal to maximal values (Nardai et al., 2016). 
 
Double immunolabeling of Rtn4r with cell markers  
S100 immunohistochemistry labeled astrocytes with the characteristic processes. We found 
that essentially all Rtn4r labeled cells were double labeled with S100 (98,1%) suggesting 
their expression in astrocytes (Fig. 18C). The Rtn4r immunoreactivity was present in the cell 
bodies and the foot processes of the astrocytes. In contrast, microglial cells labeled by the 
marker Iba1 do not contain Rtn4r (Fig. 18d). Neuronal cell bodies in the peri-infarct cortex 
did not co-localize with the Rtn4r either, however we noted altogether a weaker NeuN 
staining in this region, which may also contribute to the lack of double labeling (Fig. 18a). 
Finally the double staining with the vWF endothelial marker did not overlap with the Rtn4r 
arguing against the expression of the latter in the vasculature.  
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Figure 18. Demonstration of the presence of Rtn4r 1 in astrocytes but not in other cell types. 
In all panels, Rtn4r is green and the other markers are labeled red. Clear co-localization is 
shown with the S100 astrocyte marker (arrows) (C) while double labeling with NeuN (A) 
with vWF (B) and Iba1 (D) show no co-localization with the Rtn4r indicated by the lack of 
yellow labeling. Scale bar = 50 µm (Nardai et al., 2016). 
  
DOI:10.14753/SE.2017.1939
43 
 
Selegiline induces Notch-Jagged signaling, anti-apoptosis markers, and the expression 
of glia associated genes 
Figure 19. Graphic (A) and numerical display of mRNA expression changes induced by 
selegiline treatment following focal ischemia. The p values are calculated by T-test. Colors 
indicated the 4 groups of genes with altered expression: Notch-Jagged signaling (red: Noth1, 
Jag1), glia associated genes (orange: Ptprz1, Mag, Mog ), anti-apoptotic (blue:Bcl2/1, Xiap) 
and  pro-apoptotic (purple: Apaf 1, Diablo, Card10) genes. Gene expressional changes not 
confirmed by MWW test are shown in gray (Proc, Procr, Icam). 
 
Gene 
Fold 
change 
P 
value 
Gene 
Fold 
change 
P 
value 
Gene 
Fold 
change 
P 
value 
Gene 
Fold 
change 
P 
value 
GAP43 1.47 0.16 Nrp1 0.94 0.81 Birc3 1.43 0.07 Bcl3 1.10 0.56 
Jun 1.04 0.67 Rtn4 0.85 0.09 Naip2 1.25 0.38 Card10 0.89 0.02 
SPRR1a 0.74 0.43 Rtn4r 1.16 0.32 Bcl2l2 0.95 0.71 Cradd 0.88 0.24 
Neurod6 0.96 0.86 Ngfr 0.87 0.62 Bcl2l1 3.00 0.00 Sod1 0.96 0.36 
Tuba1a 1.05 0.31 Mag 1.36 0.02 Ripk1 0.83 0.07 Sod2 0.88 0.28 
L1cam 0.89 0.49 Mog 1.29 0.01 Bax 0.07 0.36 Stat3 1.10 0.30 
Marcks 1.00 1.00 Lilrb3 2.00 0.38 Bid 0.83 0.21 Csnk2b 1.08 0.29 
Cuzd1 1.97 0.24 Notch1 1.39 0.01 Casp1 0.81 0.20 Cybb 0.83 0.69 
Nefm 0.95 0.81 Jag1 1.50 0.00 Casp2 1.10 0.24 Gpx1 0.73 0.13 
DCC 1.21 0.44 Tnf 0.42 0.08 Casp3 0.89 0.31 Cat 0.90 0.09 
Igf1 1.13 0.53 Icam1 0.73 0.06 Casp6 0.91 0.07 Hif1a 1.05 0.32 
Igfbp6 0.73 0.13 Vcam1 1.29 0.07 Casp7 1.01 0.92 Mmmp9 0.75 0.18 
Cxcl12 1.28 0.42 Sele 0.89 0.68 Casp8 1.05 0.38 Plat 1.47 0.06 
Vegfa 0.92 0.56 Tgfb1 0.75 0.10 Casp9 1.01 0.85 Timp1 1.10 0.54 
Kdr 0.86 0.31 Infg 0.75 0.46 Casp12 1.30 0.21 Timp2 0.89 0.11 
Flt1 1.10 0.40 Hspa1a 0.95 0.86 BCL2l11 0.89 0.48 Timp3 0.84 0.09 
Ngf 0.89 0.54 Procr 0.57 0.02 Fadd 1.02 0.77 Timp4 0.81 0.24 
Bdnf 0.83 0.66 F2r 1.31 0.07 Apaf1 0.81 0.04 Mmp2 0.86 0.51 
Ncan 1.15 0.18 Xiap 1.29 0.01 Diablo 1.45 0.03 Mmp12 0.33 0.13 
Ptprz1 1.94 0.03 Proc 0.17 0.04 Cycs 1.10 0.28    
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We successfully tested 80 representative genes involved in synaptic plasticity, apoptosis, 
reperfusion injury and the regulation of neurovascular remodeling following selegiline 
treatment in focal ischemia (Fig. 19). We evaluated the results using student T-test for the 
screening calculation and MWW test for confirmatory analysis. Only the expressional 
changes found to be significant by both test were regarded relevant. We found a significant 
change in the expression of 4 group of genes in the selegiline treated animals compared to 
the controls (Fig. 19). 
Genes with anti-apoptotic properties were selected for the test because of the previously 
established anti-apoptotic property of selegiline. Indeed, we found significant changes in the 
level of 2 anti-apoptotic genes, XIAP (p=0.01 on T-test and p=0.02 by MWW) and BCL 2/1 
(p=0.00 by both T-test and MWW). Further supporting this effect, a simultaneous down 
regulation of two pro-apoptotic genes Apaf1 (p=0.04 both on T-test and MWW) and Card 10 
(p=0.02 by both tests) was documented. Interestingly we found Smac/Diablo, a pro-apoptotic 
antagonist of the XIAP to be also upregulated (p=0.03 by T-test, 0.04 by MWW), suggesting 
a potential feed-back mechanism that would need further exploration. Since the anti-
apoptotic properties of selegiline have been studied before, we used the confirmation of 
previously established effects to validate our model but did not plan further investigations on 
these findings. 
Genes involved in the regulation of neurovascular remodeling are very important factors 
influencing functional recovery. In this group we identified 2 genes, which significantly 
changed their expression level in the peri-infarct regions in response to selegiline treatment. 
The increase of the mRNA level of Notch 1 was highly significant (p=0.01 by both T-test 
and MWW), but the ligand of Notch 1, Jagged 1 also elevated its expression level (p=0.01 
by both tests).  
The forth group of genes with altered expression were the glia associated genes, who are 
traditionally regarded as inhibitors of plasticity. The upregulation of the myelin associated 
glycoprotein (Mag) (p=0.02 by T-test, p=0.03 by MWW), the oligodendrocyte glycoprotein 
(Mog) (p=0.01 by both tests) and the induction of Ptrz1 (p=0.01 by T-test, p=0.02 by MWW) 
already suggest that the treatment effect of selegiline involves the astrocytes.  
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NICD and Jagged 1 immunoreactivities following MCAO and their alterations by 
selegiline 
NICD immunoreactivity is very low in the intact brain tissue both in the striatum and the 
cerebral cortex. Following MCAO, NICD appears in the peri-infarct region around the lesion 
without any labeling within the lesion (Fig. 20A). In fact, the border of the lesion can be 
defined in a straightforward way based on NICD immunohistochemistry. The labeling in the 
peri-infarct region is present in cell bodies and some parenchymal staining is also present. 
Following selegiline treatment, the distribution of NICD labeling did not change as compared 
to control MCAO (Fig. 20B). It was abundant at the border of the lesion but not in the intact 
cerebral cortex and striatum, and remained absent within the lesion. However, the intensity 
of NICD immunolabeling was elevated in the peri-infarct region around the lesion with a 
local distribution in cell bodies and parenchyma similar to that without treatment (Fig. 20B). 
 
Figure 20. NICD immunoreactivities in the peri-infarct region of the striatum. A: NICD 
labeling is elevated in the peri-infarct region. Notch immunoreactivity is present in the gray 
matter but not within fiber bundles. Notch labeling is absent in the infracted tissue. The 
appearance of labeling indicates the border of the lesion (dotted line). B: The distribution of 
NICD following selegiline treatment is similar to that of non-treated MCAO but an increased 
intensity of NICD labeling is in response to selegiline. Star symbols (*) indicate the lesioned 
areas. Scale bar = 400 m (Nardai et al., 2015). 
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Jagged 1 immunoreactivity is present in few scattered cells in the intact tissue. MCAO 
increases the number of labeled cells in the peri-infarct region (Fig. 21A). However, cells are 
not visible any more within the lesion. Instead, a background-like labeling of the infracted 
tissue appears without clear topography. In rats treated with selegiline, the labeling of the 
infracted tissue is the same as in controls. More importantly, the number of labeled cells as 
well as their labeling intensity is increased in the peri-infarct region (Fig. 21B). This 
enhancement of Jagged 1 immunoreactivity does not occur in the intact tissue where the 
density of labeled cells and their labeling intensity is similar to that of non-treated animals. 
 
 
Figure 21. Jagged 1 immunoreactivity in the peri-infarct region of the striatum. A: There is 
some labeling present within the lesion without clear morphological features. Outside the 
lesion, some Jagged 1-immunopositive cell bodies are seen in the control MCAO rat, mostly 
in the gray matter around fiber bundles. B: In response to selegiline, an increased number of 
intensively labeled cells are present in the peri-infarct region. The background staining of the 
infracted tissue is similar to that of without selegiline. The lesion is indicated by star symbols 
(*) while the border of the lesion in shown by dotted lines. Scale bar = 400 m (Nardai et al., 
2015). 
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Quantitative measurement of immunolabeling indicated increased level NICD and Jagged 1 
in the peri-infarct region of selegiline-treated rats as compared to control animals with 
MCAO lesion (Fig. 22). The ratio of immunolabeled area increased from 32.10% to 51.31% 
(p=0.027) for NICD, from 2.33 % to 17.68 % (p=0.031) for Jagged 1. 
 
Figure 22.  The effect of selegiline on the immunolabeled area % in the peri-infarct region 
using NICD, and Jagged 1 immunosera. Columns demonstrate significantly increased 
immunolabeling in the selegiline treated animals compared to controls. Bars display 
immunoreactivity area percentage, error bars represent SEM (Nardai et al., 2015). 
Double immunolabeling of NICD and Jagged 1 with cell markers  
NICD and Jagged expression have been documented on various cell types within the central 
nervous system before, therefore we used double labeling to better characterize the 
expression changes induced by selegiline. 
GFAP immunohistochemistry labeled astrocytes with the characteristic processes. We found 
that essentially all NICD and Jagged 1 neurons were double labeled with GFAP (97.1%, and 
94.9%, respectively) suggesting their expression in astrocytes (Fig.23A). Both 
immunoreactivities were present in cell bodies as well as in processes of astrocytes. In 
contrast, microglial cells labeled by the marker Iba1 and endothelium shown by RECA do 
not contain NICD and Jagged 1 (Fig. 23B). Neuronal cell bodies were not examined due to 
the disappearance of NeuN in the penumbra, however, the presynaptic marker synaptophysin 
did not co-localize with either NICD or Jagged 1 arguing against their presence in presynaptic 
terminals (Fig. 23C).  
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Figure 23. Demonstration of the presence of NICD and Jagged 1 in astrocytes but not in 
other cell types. In all panels, NICD or Jagged 1 are green and the markers are labeled red.  
A: Double labeling with GFAP. Both NICD (Aa) and Jagged 1 (Ab) co-localize with GFAP 
(yellow). B: Double labeling with RECA do not show NICD and Jagged1 in close proximity 
of the vascular structures, but no co-localization. C: Double labeling with Iba1. Neither NICD 
(Ba) nor Jagged 1 (Bb) co-localize with Iba1 indicated by the lack of yellow labeling. D: 
Neither NICD (Ca) nor Jagged 1 (Cb) co-localize with synaptophysin indicated by the lack 
of yellow labeling. Scale bar = 20 m (Nardai et al., 2015). 
Measurement of microvascular density by RECA immunolabeling 
Microvascular density has a profound impact on cerebral edema resorption, therefore we 
decided the measure the effect of selegiline treatment on the peri-infarct capillaries. Blood 
vessels labeled by RECA largely disappear within the lesion. Their density is markedly 
reduced in the infracted tissue (Fig. 24A). In contrast, the peri-infarct region possesses an 
elevated density of capillary network as compared to that in the intact tissue. The difference 
between the lesion and its surroundings is so outstanding that the border of the lesion can be 
delineated based on RECA staining (Fig. 24A). Selegiline has a pronounced effect on the 
density of capillaries. In selegiline-treated animals, the density of the capillary network is 
somewhat higher in parts of the lesion that are in the vicinity of its borders (Fig. 24B). 
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Furthermore, the number of capillaries is increased in the peri-infarct region of selegiline-
treated animals as compared to the same area of control animals (Fig. 24B). 
Quantitative measurement of immunolabeling indicated increased level of RECA in the peri-
infarct region of selegiline-treated rats as compared to control animals with MCAO lesion 
(Fig. 24, Fig. 26B). The ratio of immune-labeled area increased from 23.00% to 31.15% 
(p=0.037). 
 
Figure 24. RECA immunoreactivities at the border of the lesion in the striatum. A: RECA 
labels endothelial cells of blood vessels within the lesion as well as outside of it. Most of the 
vessels are small capillaries. Noticeably, the density of capillary network is low within and 
high outside the lesion. B: Selegiline treatment increases the density of capillaries the border 
of the lesion both within and outside the border of the lesion. The lesion is indicated by star 
symbols (*) while the border of the lesion in shown by dotted lines. Scale bar = 400 m 
(Nardai et al., 2015). 
MRI measurement of edema 
tMCAO treatment resulted in a significant edema, whose extent was possible to be visualized 
by whole brain MRI of the experimental animals 8 days after tMCAO (Fig. 25A). We found 
significantly decreased edema by selegiline treatment compared to controls (Fig. 25B; Fig. 
26A; p=0.047).  
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Figure 25. Peri-lesional edema visualized by T2 weighted 3D VISTA sequence on a 1,5 
Tesla MRI system using SENSE-Flex-M coil 8 days after 60min tMCAO on selegiline 
treatment (B) compared to control (A). Despite suboptimal image quality due to the use of 
human clinical scanner, the image resolution was sufficient for standardized edema 
measurements. Indeed, the white areas indicated by the yellow lines in the left hemispheres 
of the representative images demonstrate a reduced edema following selegiline treatment 
(Nardai et al., 2015). 
 
Figure 26. The effect of selegiline treatment on cerebral edema and microvascular density. 
Columns demonstrate significantly decreased planimetric area of cerebral edema in the 
selegiline treated animals (A), while the microvascular density shown by RECA 
immunoreactivity is increased in comparison to controls. Error bars represent SEM (Nardai 
et al., 2015). 
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DISCUSSION  
The complex role of astrocytes in the neurovascular unit 
Historically, glial cells were thought to constitute a barrier to repair in neuronal injuries due 
to their inhibition of axonal sprouting (Pekny et al., 2014). It is now widely accepted that 
reactive astrocytes are beneficial in preserving neuronal tissue by isolating the injury, thereby 
preventing further damage to the adjacent structures (Bush et al., 1999; Li et al., 2008; Ridet 
et al., 1997; White and Jakeman, 2008). Indeed, astrocyte proliferation is also required for 
neovascularization and barrier-genesis following ischemic injury (Lee et al., 2009; 
Quaegebeur et al., 2011). A complex interplay of concomitant processes involving the 
neurovascular unit influence recovery, and whether the proliferating astrocytes would lead 
to scar formation or the restoration of the physiologic barriers is highly determined by extent 
of the parallel microvascular rearrangement.  
We tested two fundamentally different pharmacological approaches, gelatinase inhibition 
and selegiline treatment. While the previous studies demonstrated opposite effect of these 
interventions on functional recovery in the subacute phase of cerebral infarction, our 
experiments have shown that they both primarily induce gene expressional changes in 
astrocytes following large vessel occlusion.  
The reason for these paradox findings lay probably in the fundamentally different effect of 
the two treatments on microvascular remodeling. Gelatinase inhibition in the subacute phase 
of focal ischemia was shown to suppress neurovascular remodeling. The exogenous 
administration of VEGF in a rescue experiment could prevent the MMP-induced worsening 
of the infarction by accelerating neovascularization (Zhao et al., 2006). 
In contrast, Selegiline treatment has been previously shown to exert a cytoprotective effect 
on human brain capillaries in vitro (Denes et al., 2006). Using RECA immunolabeling, we 
also found an increased microvascular density in the peri-infarct region of the selegiline 
treated rats compared to controls (Fig. 24).  These findings further underlie the importance 
of interpreting our results in accordance with to the neurovascular unit concept.  
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Induced Rtn4r expression in the astrocytes of the peri-infarct region following 
gelatinase inhibition 
We have found significantly increased Rtn4r expression in the astrocytes of the peri-infarct 
region following gelatinase inhibition in the subacute phase of cerebral infarction. According 
to literature data the gelatinase enzymes show a biphasic activation pattern following focal 
cerebral ischemia: the acute activation in the ischemic core is primarily associated with the 
invading granulocytes (Opdenakker et al., 2001), and the second, sub-acute activity peak 
involves the NeuN+ neurons and GFAP+ astrocytes of the peri-infarct cortex (Zhao et al., 
2006).  While the inhibition of the leucocyte-associated acute MMP activity helped to 
preserve the neural tissue in previous stroke experiments, functional recovery was impaired 
by the pharmacological inhibition of the delayed, cortical gelatinase activity (Zhao et al., 
2006). The elevated Rtn4r expression documented in our study represent a potential new 
mechanism contributing to this deleterious effect.   
The Rtn4r is a principal member of the NOGO system: the myelin components inhibit neurite 
outgrowth by binding to the neuronal Rtn4 receptor, that transduces the inhibitory signal to 
the cell interior via its co-receptor, Ngfr (GrandPre et al., 2002). Previously published data 
confirmed, that the metalloproteinase mediated shedding of the Rtn4r results in the release 
of a soluble N-terminal fragment of the receptor, which adheres to the Ngfr-Rtn4r complex 
and blocks its signal transmission (Walmsley et al., 2004). 
While the NOGO mediated axonal regrowth-inhibition after stroke has been primarily 
attributed to the neuronal Rtn4 receptors, the same protein was shown to promote the 
astroglial differentiation of the neural progenitor cells in vitro (Wang et al., 2008). Our results 
suggest, that the higher abundancy of Rtn4r positive astrocytes found in the peri-infarct 
cortex of the treated animals following delayed gelatinase inhibition may be a consequence 
of the increased astroglial differentiation of the neural progenitors, as a result of the 
augmented NOGO signaling, due to the lack of the Rtn4 receptor shedding.  
In the peri-infarct cortex we have found an almost exclusive co-localization of the Rtn4r with 
the S100 astrocyte marker. No neuronal co-labeling was documented, despite the literature 
data supporting the expression of the receptor on neurons in the normal rat brain (Funahashi 
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et al., 2008). Important to note however, that the standardly used NeuN neuronal marker has 
a tendency to lose immunogenicity in the peri-infarct region (Unal-Cevik et al., 2004), 
therefore the lack double labeling in our experiments does not exclude the potential 
expression of the Rtn4r on neurons.  
While the new data on the upregulation of the Rtn4 receptor expression in the peri-infarct 
cortex helps to explain the impaired regeneration associated with delayed MMP inhibition in 
ischemic stroke, many questions are still unanswered. The exact mechanism by which the 
gelatinase inhibitors enhance the mRNA expression of the Rtn4r remains to be explored, and 
future experiments are needed to clarify how the potentially increased NOGO signaling 
associated with the delayed gelatinase inhibition may affect the neurons in the peri-infarct 
region.   
Important to note, that the potentially increased astroglial differentiation of the neural 
progenitors in the peri-infarct cortex was detected following delayed gelatinase inhibition, a 
treatment known to suppress neurovascular remodeling. Without the parallel reconstitution 
of the microvascular bed, the proliferation of astrocytes would rather lead to glial scar 
formation, than to the restoration of physiologic barriers, explaining the detrimental effect of 
the treatment on functional outcomes.  
Notch signaling following MCAO 
Notch signaling plays an important role in the development of the nervous system. However, 
the expression of its components are diminished in the adult brain (Irvin et al., 2004; Irvin et 
al., 2001; Stump et al., 2002). We found that Notch 1 and Jagged 1 mRNA levels were 
increased in the peri-infarct region of MCAO treated rats. The elevation in mRNA levels 
translated to an increase in protein levels based on the immune-histochemical analyses. These 
results confirmed previous data for Notch 1, which has been shown to be induced by global 
ischemia (Oya et al., 2009) as well as in the peri-infarct region of MCAO lesions (Zhang et 
al., 2012). Furthermore, our result that Notch 1 is expressed in astrocytes in the peri-infarct 
region following MCAO is also in agreement with previous findings (Shimada et al., 2011). 
In contrast, Jagged 1, a ligand of Notch 1, has not been previously reported following MCAO. 
Thus, our result that Jagged 1 is also induced by MCAO in the same region where Notch 1 
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appears is novel and further suggests the activation of Notch-Jagged signaling in response to 
ischemia. Because the Notch signaling system is known to be involved in a variety of 
developmental and morphological alterations of cells, it may play a similar role in astrocytes 
following injury. Indeed, the actual function of Notch 1 induced in astrocytes has recently 
been addressed. A γ-secretase inhibitor of Notch signaling, as well as selective inhibition of 
Notch 1 signaling in astrocytes, reduced reactive astrocyte formation in the peri-infarct area 
3 days after MCAO, suggesting that Notch 1 signal transduction plays a critical role in 
reactive gliosis (Shimada et al., 2011). As both the ligand and the receptor are induced in 
astrocytes following an ischemic challenge, the Notch-Jagged signaling system is ideally 
positioned to play a part in astrocyte-astrocyte communication following neuronal injury.  
The influence of Notch signaling on the outcome of stroke is highly dependent on the site of 
activation and the cell types involved. Although Notch 1 activation in neurons and 
inflammatory cells may worsen the outcome (Arumugam et al., 2011; Wei et al., 2011), 
Notch 1 signaling in neural stem cells and progenitor cells promotes recovery (Wang et al., 
2009). Notch 1 activation in proliferating reactive astrocytes is also thought to play a 
beneficial role as it was shown to protect the brain following focal ischemia possibly by 
decreasing immune cell invasion into the injured territories (Shimada et al., 2011). Notch 1 
may also promote regeneration by inducing angiogenesis. In was shown that Notch 1 induces 
a pro-angiogenic state in normal vasculature (ZhuGe et al., 2009). Furthermore, the Notch 
signaling pathway was also shown to be involved in stroke-induced angiogenesis in the 
ischemic brain (Guo et al., 2012; Zacharek et al., 2009). 
The effect of selegiline following focal ischemia 
Selegiline increased mRNA levels of Notch 1 and its ligand Jagged 1, but no other examined 
genes were involved in the remodeling of the neurovascular unit. This finding suggests a 
specific effect of selegiline on the Notch-Jagged signaling in the penumbra. The upregulation 
of Notch-Jagged signaling is an important newly established effect of selegiline treatment, 
which has not been described before. The immune-histochemical investigations 
demonstrated an induction of Notch 1 and Jagged 1 at the protein level, thereby confirming 
our mRNA findings. Histology also provided additional spatial information on the induction 
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of the Notch-Jagged pathway. Notch 1- and Jagged 1–labeled cells appeared in the peri-
infarct region, but not within the lesion in response to selegiline. Thus, selegiline further 
induced Notch 1 and Jagged 1 in the area where these genes already show elevated expression 
in response to ischemic insult. Notch 1 and Jagged 1 were induced by selegiline almost 
exclusively in astrocytes of the peri-infarct region, suggesting that selegiline enhances Notch-
Jagged signaling in this cell type, thereby enhancing existent neurorestorative mechanisms. 
In view of the well-documented involvement of Notch-Jagged signaling in cell proliferation 
and activation, it is tempting to speculate that selegiline promotes the proliferation of reactive 
astrocytes and the re-establishment of the blood brain barrier following stroke through this 
signaling pathway. The upregulation of other astrocyte specific markers included in the array 
(Omg, Mog and Ptrz1) also seem to confirm this hypothesis. 
It is interesting to note that selegiline is not the only drug with neurorestorative properties 
that increases Notch signaling. Simvastatin was also shown to increase Notch signaling and 
promote arterial-genesis after stroke (Zacharek et al., 2009). In addition, folic acid was 
demonstrated to enhance Notch signaling and cognitive function (learning and memory in Y-
maze tests) following MCAO in rats (Zhang et al., 2012). Similarly, selegiline may also 
contribute to improved functional outcome following stroke, which awaits further 
investigation. 
As selegiline activates astrocytes via the Notch pathway, it is expected to reduce edema based 
on the established role of reactive astrocytes. Indeed, we found decreased edema using MRI 
associated with selegiline treatment. In addition to the reinforcement of barrier function, the 
resorption of edema may be largely influenced by the microvascular network. Selegiline has 
been previously shown to exert a cytoprotective effect on human brain capillaries in vitro 
(Denes et al., 2006). Therefore, we decided to test its effect on the capillary network in vivo, 
following focal ischemia. Using RECA immunolabeling, we found an increased 
microvascular density in the peri-infarct region of the selegiline treated rats compared to 
controls. This effect is most likely not directly associated with Notch 1 signaling but is likely 
to contribute to the net beneficial impact of selegiline on neurovascular-unit integrity 
(Krupinski et al., 1994). 
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In addition to affecting the Notch pathway and microcirculation, selegiline also increased the 
expression of anti-apoptotic genes BCL XL and XIAP, confirming previous reports (Simon 
et al., 2001), which contributes to the validation of our data. As far as the mechanism of 
induction of anti-apoptotic genes, a direct effect of selegiline has been previously suggested 
(Simon et al., 2001; Tatton et al., 1994). Assuming the validity of these previous 
observations, the Bcl-2 family proteins may be the primary target of selegiline, which in turn 
induce Notch 1 activity as shown in thymic lymphoma cells (Sionov et al., 2012). It is clear, 
however, that a direct connection between the two pathways in the settings of cerebral 
ischemia/reperfusion remains to be established.  
Because selegiline improves neurological function, we expected an upregulation in the 
markers of synaptic plasticity. In the case of the 9 investigated plasticity genes, however, we 
did not see any significant change induced by the therapy. When we interpret these negative 
results, it is important to note that our array provides only a snapshot of the dynamic 
interaction of genes following focal ischemia, and sampling at other time points of the post-
stroke evolution may reveal a significantly different pattern of gene expression.  
HIGHLIGHTS OF NEW FINDINGS 
 We documented the upregulation of the Reticulon 4 receptor mRNA expression following 
gelatinase inhibition in the subacute phase of cerebral infarction in the peri-infarct cortex. 
 Immunohistochemistry confirmed the increased Reticulon 4 receptor protein abundancy 
in the peri-infarct cortex following subacute gelatinase inhibitions.  
 Double labeling confirmed that the upregulation of the Rtn4 receptor mainly involved the 
peri-infarct astrocytes, potentially suggesting increased glial scar formation.  
 Selegiline treatment in the subacute phase of cerebral infarction induced the expression of 
Notch1 and Jagged mRNA in the peri-infarct region. 
 Immunohistochemistry confirmed the increased Notch 1 and Jagged protein abundancy in 
the peri-infarct region in response to selegiline treatment. 
 Double labeling showed the upregulation of the Notch1 and Jagged protein in astrocytes. 
 Selegiline starting 2d after tMCAO reduced edema after 6d of treatment. 
 Selegiline increased the density of capillary network in the peri-infarct region. 
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CONCLUSIONS 
Improving the functional integrity of the blood brain barrier, without limiting the 
microvascular remodeling and neuronal plasticity is a very challenging, but very important 
task in developing future of stroke therapies. We experimentally tested two pharmacological 
interventions aimed at improving functional outcomes following large vessel occlusion. 
While the inhibition of the acute MMP activity helped to preserve the neural tissue in 
previous stroke experiments, functional recovery was impaired by blocking the gelatinases 
in the delayed phase of stroke (Zhao et al., 2006). The known suppression of neurovascular 
remodeling, together with the currently documented increased number of Rtn4 receptor 
positive astrocytes in the peri-infarct cortex suggest, that the MMP – NOGO interaction may 
play an important role in post-stroke regeneration. Our data implicates, that an eventual 
prolonged inhibition of the gelatinases following cerebral infarction may risk to cause 
increased reactive gliosis, and therefore may interfere with functional recovery. 
In the last few decades, hundreds of molecules were shown to induce recovery in animal 
models of cerebral infarction. However, most of these compounds did not prove to be 
clinically effective in humans (Endres et al., 2008). Selegiline, on the other hand, was shown 
to improve functional outcomes in stroke patients in a small randomized clinical trial 
(Sivenius et al., 2001). We therefore believe that the newly described beneficial effects on 
blood brain barrier function, together with the observed increase in microvascular density, 
may have further significance in stroke treatment. 
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SUMMARY 
 
Emergent large vessel occlusions (ELVO) are defined by a proximal thrombotic blockage of 
the intra-cranial arteries, and without adequate treatment, they lead to poor functional 
outcomes and high mortality rate. Although mechanical thrombectomy represent a huge step 
forward in the treatment of this devastating disease, there remains a large demand for the 
development of new adjunctive therapies to improve the safety of revascularization and to 
offer alternative solutions for the reperfusion-non-eligible patients.  
We used an array based method to analyze the mRNA expressional changes induced by two 
pharmacological interventions on a standard experimental model of ELVO. In previous 
experiments gelatinase inhibition was shown decrease bleeding transformation in the acute 
phase of the cerebral infarction, while in the subacute phase it worsened functional outcomes. 
Selegiline, a widely used compound in the treatment of Parkinson’s disease was shown to 
exert neurorestorative action following stroke. The results of the gene expression study were 
confirmed by immunolabeling on the protein level.  
The subacute gelatinase inhibition studied in our experiments caused a significant 
upregulation of the Reticulon 4 receptor expression of the astrocytes in the peri-infarct cortex, 
while selegiline treatment induced the expression of the Notch 1 receptor and its ligand 
Jagged 1 on the perilesional astrocytes  besides a number of anti-apoptosis genes.   
Although our findings suggest, that both studied pharmacological interventions influence 
reactive gliosis, the effect of selegiline was accompanied by a significant reduction of edema 
on MRI and an increased density of the capillary network, suggesting the restoration of 
physiological barriers. Gelatinase inhibition on the other hand is known to decrease 
microvascular remodeling in the subacute phase of stroke, therefore our results confirm the 
previously published observations that the proliferative effect of gelatinase inhibition on 
astrocytes is more likely to result in scar formation, than in neurorestorative action.  
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ÖSSZEFOGLALÁS 
 
Az akut agyi nagyér okklúzió definíció szerint a koponyán belüli artériák proximális 
elzáródását jelenti, amely gyors ellátás hiányában maradandó neurológiai károsodáshoz és 
magas halálozási arányhoz vezethet. Bár a mechanikus trombektómia alkalmazása jelentős 
előrelépést jelent ezeknek a súlyos kórállapotoknak a kezelésében, továbbra is nagy szükség 
van olyan kiegészítő terápiás eljárások kifejlesztésére, amelyektől a revaszkularizáció 
biztonságosságának növekedése várható, illetve amelyek alternatív megoldást jelenthetnek a 
trombektómiára alkalmatlan betegek kezelése során.  
Egy array alapú vizsgálat során tanulmányoztuk két gyógyszeres beavatkozás hatásait agyi 
nagyér okklúziós standard kisállat modelljén. A zselatináz enzim gátlása kísérletes 
körülmények között alkalmas volt a vérzéses transzformáció megelőzésére az agyi infarktus 
akut fázisában, míg a későbbi fázisban ugyanez a kezelés rontotta a neurológiai kimenetelt. 
A selegiline egy Parkinson kórban széles körben alkalmazott hatóanyag, amely irodalmi 
adatok alapján elősegítette a központi idegrendszer regenerációját agyi infarktust követően.  
Kísérleteinkben a Reticulon 4 receptor expressziójának növekedését tapasztaltuk a peri-
infarktusos agykéreg asztroglia sejtjeiben a szubakut zselatináz enzim gátlást követően, míg 
a selegiline kezelés mellett a reaktív asztrocitákon a Notch 1 receptor és ligandja a Jagged 1 
expressziójának fokozódását dokumentáltuk, több anti-apoptózis gén fokozott kifejeződése 
mellett.  
Az eredményeink alapján mindkét gyógyszeres kezelés befolyással van a reaktív asztrociták 
működésére, a selegiline kezelés hatása ugyanakkor együtt járt az infarktus körüli ödéma 
csökkenésével, és egy nagyobb sűrűségű kapilláris hálózat kialakulásával, ami a fiziológiás 
vér-agy gát regenerációjára utalhat. A zselatináz enzim gátlása ezzel szemben ismerten 
blokkolja az ér-újdonképződést, így ez utóbbi kezelés hatására inkább alakul ki a regenerációt 
gátló gliaheg semmint hatékonyan funkcionáló vér-agy gát.     
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APPENDIX 
National Institute of Health Stroke Scale 
Proposed neurological evaluation algorithm to determine the stroke severity score based on 
the recommendations of the National Institute of Neurological Disorders.  
Category  Score/description 
1.a. Level of consciousness responsiveness 0= Alert 
1=Drowsy 
2=Stuporous 
3=Coma 
1.b. LOC questions 
       (Month, age) 
0=Answers both correctly 
1=Answers one correctly 
2=Incorrect 
1.c. LOC commands 
      (Open/close eye, make fist/let go) 
0=Obeys both correctly 
1=Obeys one correctly 
2=Incorrect 
2. Best gaze 
      (Eye open – patient follows 
       examiner’s finger to face)  
0=Normal 
1=Partial gaze palsy 
2=Forced deviation 
3. Visual fields 
     (Introduce visual stimulus/threat to 
      patient’s visual field quadrants) 
0=No visual loss 
1=Partial hemianopia 
2=Complete hemianopia 
3=Complete 
5a. Motor arm – left 
5b. Motor arm – right 
      (Elevate arm to 90° if patient is sitting,        
      to 45° if supine)   
0=No drift 
1=Drift 
2=Can’t resist gravity 
3=No effort against gravity 
4=No movement 
x=Untestable (joint fusion/amput.) 
Left 
 
 
Right 
6a. Motor leg – left 
6b. Motor leg – right 
      (Elevate leg to 30° with patient supine)   
0=No drift 
1=Drift 
2=Can’t resist gravity 
3=No effort against gravity 
4=No movement 
x=Untestable (joint fusion/amput.) 
Left 
 
 
Right 
7. Limb ataxia 
    (Finger-nose, Heel down shin)  
0=No ataxia 
1=Persistent in one limb 
2=Persistent in two limbs 
8. Sensory 
    (Pin prick to face, arm, trunk, and leg- 
     compare side to side) 
0=Normal 
1=Partial loss 
3=Severe loss 
9. Best language 
    (Name item, describe a picture and read 
     sentences) 
0=No aphasia 
1=Mild to moderate aphasia 
2=Severe aphasia 
3=Mute 
10. Dysarthria  
     (Evaluate speech clarity by patient 
      repeating listed words.)  
0=Normal articulation 
1=Mild to moderate slurring of words 
2=Near to unintelligible or worse 
x=Intubated or other physical barrier 
11. Extinction and inattention 
    (Use information from prior testing to identify 
    neglect or double simultaneous stimuli testing.) 
0=No neglect 
1=Partial neglect 
2=Complete neglect 
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